<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">75181</article-id><article-id pub-id-type="doi">10.7554/eLife.75181</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Cancer type classification using plasma cell-free RNAs derived from human and microbes</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-260791"><name><surname>Chen</surname><given-names>Shanwen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-260792"><name><surname>Jin</surname><given-names>Yunfan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-260793"><name><surname>Wang</surname><given-names>Siqi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-260794"><name><surname>Xing</surname><given-names>Shaozhen</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260795"><name><surname>Wu</surname><given-names>Yingchao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260796"><name><surname>Tao</surname><given-names>Yuhuan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260797"><name><surname>Ma</surname><given-names>Yongchen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260798"><name><surname>Zuo</surname><given-names>Shuai</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260799"><name><surname>Liu</surname><given-names>Xiaofan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260800"><name><surname>Hu</surname><given-names>Yichen</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260801"><name><surname>Chen</surname><given-names>Hongyan</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260802"><name><surname>Luo</surname><given-names>Yuandeng</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260803"><name><surname>Xia</surname><given-names>Feng</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260804"><name><surname>Xie</surname><given-names>Chuanming</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260805"><name><surname>Yin</surname><given-names>Jianhua</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260806"><name><surname>Wang</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260807"><name><surname>Liu</surname><given-names>Zhihua</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260808"><name><surname>Zhang</surname><given-names>Ning</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-163826"><name><surname>Zech Xu</surname><given-names>Zhenjiang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1080-024X</contrib-id><email>zhenjiang.xu@gmail.com</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund16"/><xref ref-type="other" rid="fund17"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-143625"><name><surname>Lu</surname><given-names>Zhi John</given-names></name><email>zhilu@tsinghua.edu.cn</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-259113"><name><surname>Wang</surname><given-names>Pengyuan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1210-4056</contrib-id><email>pengyuan_wang@bjmu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund18"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02z1vqm45</institution-id><institution>Division of General Surgery, Peking University First Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02z1vqm45</institution-id><institution>Translational Cancer Research Center, Peking University First Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cve4549</institution-id><institution>MOE Key Laboratory of Bioinformatics, Center for Synthetic and Systems Biology, School of Life Sciences, Tsinghua University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042v6xz23</institution-id><institution>State Key Laboratory of Food Science and Technology, Nanchang University</institution></institution-wrap><addr-line><named-content content-type="city">Nanchang</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02drdmm93</institution-id><institution>State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution>Institute of Hepatobiliary Surgery, The First Hospital Affiliated to Army Medical University</institution><addr-line><named-content content-type="city">Chongqing</named-content></addr-line><country>China</country></aff><aff id="aff7"><label>7</label><institution>Department of Epidemiology, Faculty of Navy Medicine, Navy Medical University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02drdmm93</institution-id><institution>Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer /Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01vjw4z39</institution-id><institution>Shenzhen Stomatology Hospital (Pingshan), Southern Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Shenzhen</named-content></addr-line><country>China</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01vjw4z39</institution-id><institution>Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lo</surname><given-names>YM Dennis</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02zhqgq86</institution-id><institution>The Chinese University of Hong Kong</institution></institution-wrap><country>Hong Kong</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Lo</surname><given-names>YM Dennis</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02zhqgq86</institution-id><institution>The Chinese University of Hong Kong</institution></institution-wrap><country>Hong Kong</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>11</day><month>07</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e75181</elocation-id><history><date date-type="received" iso-8601-date="2021-11-01"><day>01</day><month>11</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-06-26"><day>26</day><month>06</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-10-29"><day>29</day><month>10</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.21203/rs.3.rs-1012781/v1"/></event></pub-history><permissions><copyright-statement>© 2022, Chen, Jin, Wang et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Chen, Jin, Wang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-75181-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-75181-figures-v1.pdf"/><abstract><p>The utility of cell-free nucleic acids in monitoring cancer has been recognized by both scientists and clinicians. In addition to human transcripts, a fraction of cell-free nucleic acids in human plasma were proven to be derived from microbes and reported to have relevance to cancer. To obtain a better understanding of plasma cell-free RNAs (cfRNAs) in cancer patients, we profiled cfRNAs in ~300 plasma samples of 5 cancer types (colorectal cancer, stomach cancer, liver cancer, lung cancer, and esophageal cancer) and healthy donors (HDs) with RNA-seq. Microbe-derived cfRNAs were consistently detected by different computational methods when potential contaminations were carefully filtered. Clinically relevant signals were identified from human and microbial reads, and enriched Kyoto Encyclopedia of Genes and Genomes pathways of downregulated human genes and higher prevalence torque teno viruses both suggest that a fraction of cancer patients were immunosuppressed. Our data support the diagnostic value of human and microbe-derived plasma cfRNAs for cancer detection, as an area under the ROC curve of approximately 0.9 for distinguishing cancer patients from HDs was achieved. Moreover, human and microbial cfRNAs both have cancer type specificity, and combining two types of features could distinguish tumors of five different primary locations with an average recall of 60.4%. Compared to using human features alone, adding microbial features improved the average recall by approximately 8%. In summary, this work provides evidence for the clinical relevance of human and microbe-derived plasma cfRNAs and their potential utilities in cancer detection as well as the determination of tumor sites.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>liquid biopsy</kwd><kwd>microbiome</kwd><kwd>cancer classification</kwd><kwd>biomarker</kwd><kwd>cell-free RNA</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>the Capital's Fund for Health Improvement and Research</institution></institution-wrap></funding-source><award-id>CFH 2022-4075</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Pengyuan</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31771461</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Shanwen</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>the National Key Research and Development Plan of China</institution></institution-wrap></funding-source><award-id>2017YFA0505803</award-id><principal-award-recipient><name><surname>Zech Xu</surname><given-names>Zhenjiang</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>the National Science and Technology Major Project of China</institution></institution-wrap></funding-source><award-id>2018ZX10723204</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Pengyuan</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>the Tsinghua University Initiative Scientific Research Program</institution></institution-wrap></funding-source><award-id>2021Z99CFY022</award-id><principal-award-recipient><name><surname>Lu</surname><given-names>Zhi John</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>the Tsinghua-Foshan Innovation Special Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lu</surname><given-names>Zhi John</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>the Fok Ying-Tong Education Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lu</surname><given-names>Zhi John</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>the Interdisciplinary Clinical Research Project of Peking University First Hospital</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Wang</surname><given-names>Pengyuan</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Beijing Advanced Innovation Center for Structural Biology</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lu</surname><given-names>Zhi John</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution>the Bioinformatics Platform of National Center for Protein Sciences</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lu</surname><given-names>Zhi John</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>3217040246</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Shanwen</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81972798</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Shanwen</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81373067</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Shanwen</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81773140</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Shanwen</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81902384</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Shanwen</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution>the National Key Research and Development Plan of China</institution></institution-wrap></funding-source><award-id>2017YFC0908401</award-id><principal-award-recipient><name><surname>Zech Xu</surname><given-names>Zhenjiang</given-names></name></principal-award-recipient></award-group><award-group id="fund17"><funding-source><institution-wrap><institution>the National Key Research and Development Plan of China</institution></institution-wrap></funding-source><award-id>2019YFC1315700</award-id><principal-award-recipient><name><surname>Zech Xu</surname><given-names>Zhenjiang</given-names></name></principal-award-recipient></award-group><award-group id="fund18"><funding-source><institution-wrap><institution>the National Science and Technology Major Project of China</institution></institution-wrap></funding-source><award-id>2018ZX10302205</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Pengyuan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Both human and microbe cell-free RNA features in plasma could distinguish tumors of different primary locations.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Recently, noninvasive liquid biopsy of plasma cell-free nucleic acids has emerged as a convenient and cost-effective method for cancer screening and monitoring. The clinical utilities of cell-free DNA (cfDNA) and cell-free RNA (cfRNA) in cancer have been extensively studied. Mutations (<xref ref-type="bibr" rid="bib1">Abbosh et al., 2017</xref>), methylation levels (<xref ref-type="bibr" rid="bib2">Anders et al., 2015</xref>), fragmentation patterns (<xref ref-type="bibr" rid="bib7">Cristiano et al., 2019</xref>) of plasma cfDNA, and expression levels of different cfRNA species (miRNA, circular RNA [circRNA], signal recognition particle RNA [srpRNA], long noncoding RNA [lncRNA], mRNA, etc.) (<xref ref-type="bibr" rid="bib4">Best et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Li et al., 2015</xref>; <xref ref-type="bibr" rid="bib63">Tan et al., 2019</xref>) in plasma, platelets, and extracellular vesicles (EVs) were identified as potential diagnostic or prognostic markers. In addition to early detection, it is also favorable if liquid biopsy could provide clues about the tumor’s primary location to guide further clinical decisions. Plasma cfDNA methylation and the platelet transcriptome were reported to have cancer type specificity (<xref ref-type="bibr" rid="bib57">Shen et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">Best et al., 2015</xref>) but whether plasma cfRNAs have such properties remains largely uncharacterized.</p><p>Studies of the human cancer-related microbiome are increasingly valued for their novel biological insights and potential clinical applications. It is well established that several bacteria and viruses are involved in cancer development and progression. For instance, chronic infection with HBV and HPV is the leading cause of liver cancer and cervical cancer, respectively (<xref ref-type="bibr" rid="bib3">Arbuthnot and Kew, 2001</xref>; <xref ref-type="bibr" rid="bib6">Burd, 2003</xref>). <italic>Helicobacter pylori</italic> infection is a well-known risk factor for developing gastric cancer (<xref ref-type="bibr" rid="bib48">Polk and Peek, 2010</xref>). <italic>Fusobacterium nucleatum</italic> was reported to drive tumorigenesis in colon cancer (<xref ref-type="bibr" rid="bib16">Han, 2015</xref>). It has also been reported that in pancreatic cancer, higher microbial diversity predicts better prognosis (<xref ref-type="bibr" rid="bib51">Riquelme et al., 2019</xref>). A more recent study reported that cancer type-specific living bacteria can be detected inside tumor cells, suggesting that there are unexpectedly complicated interactions between microbes and tumor cells (<xref ref-type="bibr" rid="bib51">Riquelme et al., 2019</xref>).</p><p>Traditionally, blood was thought to be sterile in individuals without sepsis (<xref ref-type="bibr" rid="bib14">Gosiewski et al., 2017</xref>; <xref ref-type="bibr" rid="bib5">Blauwkamp et al., 2019</xref>). Although it remains controversial whether the blood of healthy donors (HDs) contains living bacteria (<xref ref-type="bibr" rid="bib4">Best et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Potgieter et al., 2015</xref>), several recent studies suggested that bacteria-derived nucleic acids can be confidently detected in human plasma, which cannot be simply attributed to contamination in reagents and other potential sources (<xref ref-type="bibr" rid="bib14">Gosiewski et al., 2017</xref>; <xref ref-type="bibr" rid="bib76">Zozaya-Valdés et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Kowarsky et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Pan et al., 2017</xref>). Many uncharacterized bacteria and viruses can be assembled from blood DNA-seq data (<xref ref-type="bibr" rid="bib23">Kowarsky et al., 2017</xref>). In obese patients, gut microbe-derived EVs, which contain microbial DNA, can enter the bloodstream and induce an inflammatory response (<xref ref-type="bibr" rid="bib34">Luo et al., 2021</xref>). A recent study also suggested that the abundance of microbial-derived plasma cfDNA could accurately distinguish between different cancer types (<xref ref-type="bibr" rid="bib49">Poore et al., 2020</xref>).</p><p>Most of the previous cfRNA studies focused on small RNA species (<xref ref-type="bibr" rid="bib38">Mitchell et al., 2008</xref>), which are relatively stable in plasma. Long RNA species in plasma have relatively low concentrations, which are mainly 100–200 nt fragments lacking poly-A tails and intact ends. Therefore, regular RNA-seq, which usually uses ligation techniques to add adaptors, will not work well for long cfRNAs. The recently developed SMART-seq (<xref ref-type="bibr" rid="bib47">Picelli et al., 2014</xref>)-based techniques offer the potential to overcome these issues. Furthermore, to sequence total RNAs in plasma, we need to simultaneously remove the abundant rRNA fragments, which are enabled by a CRISPR-based technology called depletion of abundant sequences by hybridization (DASH; <xref ref-type="bibr" rid="bib15">Gu et al., 2016</xref>). This motivated us to study the biological relevance and clinical utilities of human and microbe-derived long cfRNAs, taking advantage of the above techniques.</p><p>Here, we investigated diverse cfRNA species (&gt;50 nt, rRNA depleted) in ~300 plasma samples of cancer patients and HDs. This cohort included five cancer types (colorectal cancer, stomach cancer, liver cancer, lung cancer, and esophageal cancer) that were responsible for 75% of cancer-related mortality in China (<xref ref-type="bibr" rid="bib60">Siegel et al., 2015</xref>). Most of the cancer patients were in the early stages. To the best of our knowledge, our study demonstrated for the first time that both human and microbe-derived RNAs in plasma detected by cfRNA-seq could reflect cancer type-specific information. We also showed that combining microbial cfRNA signatures could improve the performance of human cfRNAs in cancer classification.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Sequencing of cfRNAs captures signals of various long RNA species in the plasma</title><p>Here, we adapted a SMART-based total RNA sequencing method (SMART-total) to profile plasma total cfRNAs. This technique was optimized for low-input RNA sequencing and robust for partially degraded RNA fragments. SMART-total was successfully applied to detect cfRNAs in the plasma of pregnant women and cancer patients in previous studies (<xref ref-type="bibr" rid="bib45">Pan et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">Ngo et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Yu et al., 2020</xref>). One of these studies, which investigated plasma cfRNAs of pregnant women, suggested that microbial signals detected by SMART-total can also provide useful information (<xref ref-type="bibr" rid="bib45">Pan et al., 2017</xref>). We applied SMART-total to a cohort of 295 plasma samples, and the percentage of patients with early-stage cancer (stages I and II) ranged from 65% in stomach cancer to 86% in lung cancer (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p><p>For low-biomass metagenomic profiling, laboratory and kit contamination can lead to unreliable conclusions (<xref ref-type="bibr" rid="bib11">Eisenhofer et al., 2019</xref>). Given the low concentration of both human and microbial cfRNAs in plasma, little contamination could have detrimental impacts on downstream analysis. To minimize the impacts of potential microbe contamination introduced in sample collection, RNA extraction, library preparation, and sequencing, two <italic>Escherichia coli</italic> samples and one human brain RNA sample were processed and sequenced following exactly the same procedure as plasma samples, serving as controls for contamination.</p><p>In addition to potential contaminations, misclassification of microbe-derived reads also renders the result less interpretable. We carefully designed a computational pipeline to mitigate these problems (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, see Materials and methods). In brief, after removing human rRNA and other unwanted sequences, reads were aligned to the human genome and circRNA back-spliced junctions to quantify human gene expression. Several quality control rules were applied to ensure data reliability, and 263 high-quality samples were reserved for further analysis (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Unaligned reads were classified with kraken (<xref ref-type="bibr" rid="bib67">Wood et al., 2019</xref>), an efficient but less stringent method based on k-mer contents and a stringent but relatively computationally intensive method based on bowtie2 alignment (<xref ref-type="bibr" rid="bib24">Langmead and Salzberg, 2012</xref>). Since the majority of microbial reads are rRNA, we only mapped microbial rRNA reads against the Silva database (<xref ref-type="bibr" rid="bib71">Yilmaz et al., 2014</xref>) to reduce the computational burden. The rest non-rRNA reads were aligned to viral genomes. From the resulting microbial profile, we filtered away genera that were found in our control samples (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>), previously reported common laboratory contaminations (<xref ref-type="bibr" rid="bib54">Salter et al., 2014</xref>), and abundant skin microbes (<xref ref-type="bibr" rid="bib43">Oh et al., 2016</xref>), which are often regarded as potential sources of contamination (<xref ref-type="bibr" rid="bib56">Schierwagen et al., 2020</xref>). Several suspicious viral genera with nonhuman eukaryotic hosts (<xref ref-type="bibr" rid="bib37">Mihara et al., 2016</xref>) were also excluded (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Pipeline for cell-free RNA (cfRNA) sequencing data processing.</title><p>(<bold>A</bold>) The bioinformatic pipeline for plasma cfRNA sequencing data processing. After adapter trimming, spike in, potential vector contaminations, and human rRNA sequences were removed. Cleaned reads were aligned to the human genome and circular RNA back-spliced junctions. Unmapped reads were classified with a k-mer-based pipeline and an alignment-based pipeline. Genera detected by both pipelines were used for downstream analysis. Potential contaminations (known common laboratory contaminants, genera detected in control samples, skin microbes, and suspicious viral genera) were excluded. See the Materials and methods section for details. (<bold>B</bold>) Average fractions of different cfRNA components in cleaned reads. Microbe-rRNA refers to reads annotated to rRNA. Microbe-others refers to non-rRNA reads that were assigned to microbial genomes by kraken2.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75181-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Quality control of sequencing data.</title><p>We used 295 samples of 5 cancer patients and healthy donors to discover potential RNA biomarkers. 263 samples passed the following quality control criteria: (1) Raw reads: at least 10 million. (2) Clean reads: at least 5 million. Spike-in sequence: &lt;50%. rRNA sequence: &lt;50%. (3) Aligned reads (reads mapped to the human genome or circRNA junctions): at least 0.5 million; Intron-spanning reads: at least 0.1 million; reads assigned to mRNA and lncRNA: at least 20%; unclassified reads (reads cannot be assigned to annotated exon, intron, antisense of exons, promoter, enhancer, or repeats): less than 30%.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75181-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Using this computational pipeline, the majority of cleaned reads were mapped to the human genome (79.36% on average) and back-spliced junctions of circRNA (1.24% on average). In the remaining reads, 10.18% were annotated as nonhuman rRNA, and 2.06% were further assigned to microbial genomes by kraken2 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>).</p><p>Consistent with the intracellular long RNA profile, mRNAs and lncRNAs were the most abundant human RNA species captured in the SMART-total library (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Several housekeeping genes, such as ACTB, TUBB1, and PTMA, as well as noncoding RNAs, such as srpRNA (RN7SL2), are highly abundant in the plasma of both cancer patients and HDs (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). For these transcripts, the coverage was uniformly distributed along the full-length transcripts in samples from different clinical centers (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Previous studies demonstrated that mRNAs mainly exist as short fragments up to several hundred nucleotides (<xref ref-type="bibr" rid="bib25">Larson et al., 2021</xref>). This uniform coverage indicates that at least for these most abundant transcripts, such a naturally occurring fragmentation process does not have a strong sequence preference. Moreover, a sharp boundary of read coverage at exon-intron junctions further demonstrated that there was minimal genomic DNA contamination in our sequencing libraries (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Human genes and microbial signals revealed by cell-free RNA (cfRNA)-seq.</title><p>(<bold>A</bold>) The number of detected human transcripts (counts per million &gt;2) of different RNA types and their relative abundances. (<bold>B</bold>). Representative coverages for ACTB and TUBB1 in healthy donors (HDs) from three clinical centers (samples HD-1, HD-2, and HD-3 are provided by PKU, ShH-1, and SWU, respectively). (<bold>C</bold>). Metagene plot for read coverage around 5’ exon boundaries and 3’ exon boundaries. The mean coverage of 100 nt around exon boundaries for exons with read coverage &gt;3 is shown. (<bold>D</bold>). Relative abundance of reads assigned to different phyla by kraken2. (<bold>E</bold>). Representative read coverage of <italic>Lawsonella clevelandensis</italic> 16S and 23S rRNA in healthy donors from three clinical centers. (<bold>F</bold>). A representative read coverage on the HBV genome in cfRNA of a patient with liver cancer.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75181-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Most abundant human genes and microbial genera in plasma cell-free (cfRNA) libraries.</title><p>(<bold>A</bold>) The abundance (log10TPM) of the 15 most abundant human genes in different sample groups. TPM: transcripts per million. (<bold>B</bold>) The abundance (log10CPM) of the 15 most abundant genera in different sample groups. CPM: counts per million.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75181-fig2-figsupp1-v1.tif"/></fig></fig-group><p>For microbe-derived reads, the most abundant phylum was <italic>Proteobacteria</italic>, followed by <italic>Firmicutes</italic> and <italic>Actinobacteria</italic> (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). This composition resembles previous reports for microbe-derived cfDNA and cfRNA in plasma (<xref ref-type="bibr" rid="bib76">Zozaya-Valdés et al., 2021</xref>; <xref ref-type="bibr" rid="bib45">Pan et al., 2017</xref>; <xref ref-type="bibr" rid="bib70">Yao et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Paisse et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Lelouvier et al., 2016</xref>). Consistent with previous studies (<xref ref-type="bibr" rid="bib30">Liang and Bushman, 2021</xref>), <italic>Caudovirales</italic>, an order of viruses known as tailed bacteriophages, makes up the majority (the median fraction is higher than 95%) of reads assigned to viruses by kraken2.</p><p>We investigated the read coverage for detected microbes by aligning nonhuman reads to their genomes. As expected, for bacteria, most of the RNA-seq signals agree with the previous notion that most microbial reads are from rRNA, and for <italic>Lawsonella clevelandensis</italic>, a pathogen reported to induce abscess (<xref ref-type="bibr" rid="bib13">Goldenberger et al., 2019</xref>) as an example (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). The RNA-seq signals for viruses are also consistent with their genome annotations. For instance, in a representative coverage of the HBV genome (<xref ref-type="fig" rid="fig2">Figure 2F</xref>), the read coverage of HBX gene agrees well with its annotated boundary.</p></sec><sec id="s2-2"><title>cfRNA profile alterations in patients are cancer relevant</title><p>To investigate the biological relevance of plasma cfRNAs in cancer patients, the enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of human genes differentially expressed in cancer patients (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>) were identified (<xref ref-type="table" rid="table1">Table 1</xref>). Enriched pathways of upregulated genes include extra-cellular matrix [ECM]-receptor interactions and neutrophil extracellular traps, which have been recognized to promote metastasis (<xref ref-type="bibr" rid="bib68">Xiao et al., 2021a</xref>). Downregulated cfRNAs are highly enriched in pathways mainly related to ribosome biogenesis. Downregulation of translation-related pathways was previously reported in tumor-educated platelets (TEPs; <xref ref-type="bibr" rid="bib4">Best et al., 2015</xref>), indicating that translational events might be globally suppressed in the blood milieu of cancer patients. More interestingly, multiple immune-related pathways (PD-1 checkpoint, T-cell differentiation, NOD-like receptor signaling, cytosolic DNA-sensing, and NF-κB signaling) are downregulated in cancer patients, depicting their suppressed immune status. These findings suggest that signals related to the tumor and tumor microenvironment can be identified by cfRNA-seq. For comparisons among different cancer types and HDs, similar patterns were also observed (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of significantly up- and downregulated human genes based on the cell-free RNA (cfRNA)-seq data of all cancer patients vs. healthy donors (HDs).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Pathways<xref ref-type="table-fn" rid="table1fn1"><sup>*</sup></xref></th><th align="left" valign="top">p value</th><th align="left" valign="top">Gene ratio<xref ref-type="table-fn" rid="table1fn2"><sup>†</sup></xref></th><th align="left" valign="top">Trend</th></tr></thead><tbody><tr><td align="left" valign="top">Platelet activation</td><td align="char" char="hyphen" valign="top">1.52E-19</td><td align="char" char="." valign="top">0.0728</td><td align="left" valign="top" rowspan="10">Up</td></tr><tr><td align="left" valign="top">Calcium signaling pathway</td><td align="char" char="hyphen" valign="top">1.28E-07</td><td align="char" char="." valign="top">0.0695</td></tr><tr><td align="left" valign="top">ECM-receptor interaction</td><td align="char" char="hyphen" valign="top">2.98E-07</td><td align="char" char="." valign="top">0.0364</td></tr><tr><td align="left" valign="top">Neutrophil extracellular trap formation</td><td align="char" char="hyphen" valign="top">4.15E-07</td><td align="char" char="." valign="top">0.0579</td></tr><tr><td align="left" valign="top">Focal adhesion</td><td align="char" char="hyphen" valign="top">5.79E-07</td><td align="char" char="." valign="top">0.0596</td></tr><tr><td align="left" valign="top">Phospholipase D signaling pathway</td><td align="char" char="hyphen" valign="top">3.52E-06</td><td align="char" char="." valign="top">0.0464</td></tr><tr><td align="left" valign="top">Human cytomegalovirus infection</td><td align="char" char="hyphen" valign="top">8.81E-06</td><td align="char" char="." valign="top">0.0596</td></tr><tr><td align="left" valign="top">Regulation of actin cytoskeleton</td><td align="char" char="hyphen" valign="top">1.09E-05</td><td align="char" char="." valign="top">0.0579</td></tr><tr><td align="left" valign="top">Rap1 signaling pathway</td><td align="char" char="hyphen" valign="top">1.21E-05</td><td align="char" char="." valign="top">0.0563</td></tr><tr><td align="left" valign="top">Viral carcinogenesis</td><td align="char" char="hyphen" valign="top">4.16E-05</td><td align="char" char="." valign="top">0.0530</td></tr><tr><td align="left" valign="top">Ribosome</td><td align="char" char="hyphen" valign="top">2.32E-69</td><td align="char" char="." valign="top">0.174</td><td align="left" valign="top" rowspan="10">Down</td></tr><tr><td align="left" valign="top">PD-1 checkpoint pathway in cancer</td><td align="char" char="hyphen" valign="top">1.74E-03</td><td align="char" char="." valign="top">0.026</td></tr><tr><td align="left" valign="top">Proteasome</td><td align="char" char="hyphen" valign="top">2.51E-03</td><td align="char" char="." valign="top">0.017</td></tr><tr><td align="left" valign="top">Pyrimidine metabolism</td><td align="char" char="hyphen" valign="top">3.43E-03</td><td align="char" char="." valign="top">0.019</td></tr><tr><td align="left" valign="top">Th17 cell differentiation</td><td align="char" char="hyphen" valign="top">3.85E-03</td><td align="char" char="." valign="top">0.028</td></tr><tr><td align="left" valign="top">Th1 and Th2 cell differentiation</td><td align="char" char="hyphen" valign="top">6.45E-03</td><td align="char" char="." valign="top">0.025</td></tr><tr><td align="left" valign="top">Transcriptional misregulation in cancer</td><td align="char" char="hyphen" valign="top">6.85E-03</td><td align="char" char="." valign="top">0.042</td></tr><tr><td align="left" valign="top">NOD-like receptor signaling pathway</td><td align="char" char="hyphen" valign="top">7.08E-03</td><td align="char" char="." valign="top">0.040</td></tr><tr><td align="left" valign="top">Cytosolic DNA-sensing pathway</td><td align="char" char="hyphen" valign="top">7.16E-03</td><td align="char" char="." valign="top">0.019</td></tr><tr><td align="left" valign="top">NF-kappa B signaling pathway</td><td align="char" char="hyphen" valign="top">7.39E-03</td><td align="char" char="." valign="top">0.026</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>Enriched pathway of pan-cancer upregulated and downregulated genes.</p></fn><fn id="table1fn2"><label>†</label><p>Fraction of upregulated or downregulated genes annotated to a KEGG pathway.</p></fn></table-wrap-foot></table-wrap><p>For microbial cfRNAs, we found that the plasma abundance of multiple viral genera, including <italic>Lymphocryptovirus</italic>, <italic>Mastadenovirus</italic>, <italic>Roseolovirus</italic>, several genera of torque teno viruses (TTVs), and <italic>Orthohepadnavirus</italic>, was significantly higher in cancer patients (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). This result is supported by both pipelines (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). The viral loads of two prevalent genera, <italic>Alphatorquevirus</italic> and <italic>Orthohepadnavirus</italic>, are associated with liver cancer (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). TTVs are highly prevalent viruses even in the healthy population and are not considered pathogens of a specific disease, but associations between TTV and liver diseases have been widely reported (<xref ref-type="bibr" rid="bib40">Mrzljak and Vilibic-Cavlek, 2020</xref>). Higher TTV abundance is also associated with suppressed immune status and has been utilized as an indicator of immunosuppression after organ transplantation (<xref ref-type="bibr" rid="bib40">Mrzljak and Vilibic-Cavlek, 2020</xref>; <xref ref-type="bibr" rid="bib19">Jaksch et al., 2018</xref>; <xref ref-type="bibr" rid="bib62">Spandole et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">De Vlaminck et al., 2013</xref>). The enrichment of TTVs in cancer patients is concordant with the downregulation of immune pathways we found in human cfRNAs. The association between liver cancer and <italic>Orthohepadnavirus</italic>, a genus to which HBV belongs, is expected, as 60% of the liver cancer patients in this study had a history of HBV-induced chronic hepatitis (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Other viral genera that were significantly altered in liver cancer are also shown (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Biological relevance of alterations in the microbial cell-free RNA (cfRNA) profile.</title><p>(<bold>A</bold>) Example genera with significantly altered abundance in cancer patients when compared to healthy donors (HDs). FC: fold change. FDR: false discovery rate. FC and FDR were calculated using the result of the alignment-based method, and labeled genera were supported by both pipelines. (<bold>B</bold>) Abundance of <italic>Alphatorquevirus</italic> and <italic>Othohepavirus</italic> in the alignment-based pipeline across different samples ranked in descending order; colors indicate different sample groups. (<bold>C</bold>) Virus genera with significant abundance alterations (FDR &lt;0.05 and log<sub>2</sub>fold-change &gt;1) in liver cancer patients when compared to HDs.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75181-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of differentially expressed human genes for each cancer type.</title><p>For five cancer types, the top 10 most significantly enriched KEGG pathways of upregulated and downregulated genes were identified. Union of these pathways was visualized. Rows for enriched pathways, columns for different cancer types, and colors indicate significance of the enrichment. Enriched pathways of liver cancer are relatively distinct from other cancer types, which may reflect some of its unique properties.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75181-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Evaluating the cancer detection capacity of human and microbial cfRNAs</title><p>We used bootstrapping to evaluate the capacity of the plasma cfRNA abundance profile in distinguishing cancer patients from HDs. For both human and microbial cfRNA abundance, we normalized the data and performed batch correction with removing unwanted variations using control genes (RUVg) (<xref ref-type="bibr" rid="bib52">Risso et al., 2014</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). For microbe data, the results of both k-mer-based and alignment-based pipelines were used. Training instances were sampled from the original dataset with replacement until the size of the training set reached the size of the original dataset. Using these training instances, we performed feature selection and fitted a balanced random forest classifier (see Materials and methods). The holdout samples were utilized for performance evaluation. This procedure was repeated 100 times.</p><p>The average AUROC scores of human cfRNAs on testing sets across 100 bootstrap replicates were approximately 0.9, and microbial cfRNAs quantified by k-mer-based pipeline achieved AUROCs from approximately 0.8 to above 0.9 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). As the majority of patients in the cohort were in early stages (stages I and II), when only using early-stage cases for bootstrapping, comparable performance was achieved (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). A similar result was observed when using the alignment-based method (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Cell-free RNA (cfRNA) features for cancer detection.</title><p>(<bold>A</bold>) Performance (AUROC) on the holdout dataset in 100 rounds of bootstrap resampling using abundance of human gene expression, microbe abundance (kraken2’s results), and combining both data for the binary classification (cancer patients vs. healthy donors). (<bold>B</bold>) Out-of-bag ROC curve using human or microbe features. For each sample, the median value of probabilities predicted by classifiers fitted in bootstrap replicates that reserved this sample in the testing set was utilized to generate the ROC curve. (<bold>C</bold>) Recurrent features with top fold changes when combining human and microbe features for bootstrap analysis. The left panel depicts Z scores of the expression levels in different subjects. The right panel illustrates their average importance ranks, frequency of identified as top 50 features, and fold change compared to healthy donors.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75181-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Data normalization for machine learning.</title><p>We used RUVg to remove unwanted variations from trimmed mean of M-values (TMM) normalized gene expression and genus abundance. The 25% most insignificant features between different sample groups in discovery set reported by edgeR’s ANOVA test were used as empirical controls. Data variations among different samples before (upper) and after (lower) RUVg processing were visualized with principal component analysis (PCA). Colors indicate different clinical centers.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75181-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Binary classification for cancer detection.</title><p>(<bold>A–E</bold>) Bootstrapping AUROC on holdout set. (<bold>A</bold>) Performance of human genes, stratified by cancer stages. (<bold>B–C</bold>) Performance of microbe features (<bold>B</bold>) and combined both microbe and human features (<bold>C</bold>) using kraken2’s results. (<bold>D–E</bold>) Performance of microbe features (<bold>D</bold>) and combined both microbe and human features (<bold>E</bold>) using bowtie2’s results. (<bold>F</bold>) Recurrently selected features with top fold changes when only considering microbe data for cancer vs. healthy donor (HD) classification.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75181-fig4-figsupp2-v1.tif"/></fig></fig-group><p>We wondered which features contributed to the model performance in cancer detection. When combining microbe and human features, among those identified as the top 50 most important ones for at least 40 times in 100 bootstrap samplings, features with top fold changes were exemplified (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). These recurrent features are dominated by human genes. Among the upregulated genes, ADAM10 (encodes a zinc-dependent protease) and TMEM165 (encodes a Golgi body transmembrane protein) have been reported to promote the invasion of tumor cells in multiple cancer types (<xref ref-type="bibr" rid="bib66">Wetzel et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Smith et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Lee et al., 2018</xref>). Consistent with our KEGG analysis, the downregulation of several genes that encode protein components of the ribosome (RPL8, RPS8, and RPL10A) in plasma is associated with cancer.</p><p>When considering microbial data alone, frequently selected features are shown (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2F</xref>). Compared to human genes, microbial abundance is more heterogeneous in different individuals, which partly explains why microbial features are rarely selected when combined with human gene expression data.</p></sec><sec id="s2-4"><title>The cancer type specificity of human and microbial cfRNA</title><p>Given that the cfRNA profile could distinguish cancer patients from HDs, we further assessed the feasibility of using cfRNAs for classifying cancer patients with different primary tumor locations. A similar bootstrapping strategy was used for performance evaluation.</p><p>Using human cfRNA features, an average recall of 52.5% was achieved (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The average recall of microbial cfRNA features in the k-mer-based pipeline was 58.4% (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). These performances were further improved when microbial features were combined with human features: compared to using human features alone, when combining both features, the average recall was 60.4%, improved by 7.9%; the average top 2 recall was 82.1%, improved by 6.2% (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Using the alignment-based pipeline, the multiclass classification performance was marginally worse (50.3% on average, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>) but still much better than random guesses, and adding microbial features also significantly boosted the average classification performance (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). Taken together, the human and microbial fractions in plasma cfRNAs both provide tumor site-specific information.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Cancer classification using human and microbial cell-free RNAs (cfRNAs).</title><p>(<bold>A–B</bold>) Confusion matrix of human (<bold>A</bold>) and microbe (<bold>B</bold>) features averaged across bootstrap replicates. (<bold>C</bold>) Top 1 and top 2 recall for each cancer type in multiclass classification. The statistical significance was determined by a one-tailed Mann-Whitney U test. (<bold>D–E</bold>) Recurrent human (<bold>D</bold>) and microbe (<bold>E</bold>) features with the top fold change in multiclass classification. The sizes and colors of the circles indicate the relative abundances (bowtie2 result, scaled to 0–1) and p values in the one vs. rest comparisons, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75181-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Performance for multiclass classification.</title><p>(<bold>A–C</bold>) Confusion matrices for microbe features using bowtie2 pipeline (<bold>A</bold>), combine microbe and human features using kraken2 pipeline (<bold>B</bold>) and bowtie2 pipeline (<bold>C</bold>), and averaged across 100 bootstrap replicates. (<bold>D</bold>) Top 1 and top 2 recall of human and microbe features using bowtie2’s results. The statistical significance was determined by one-tailed Mann–Whitney U test. (<bold>E</bold>) Gene set enrichment analysis (GSEA) for the enrichment of up to 300 circular RNAs (circRNAs) that upregulated in stomach cancer and colorectum cancer. circRNAs were ranked by fold change in tumor tissue vs. normal tissue comparison using mioncocirc data. ES: enrichment score; NES: normalized enrichment score.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75181-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Given that cfRNAs can distinguish the primary locations of tumors in cancer patients, some cfRNA features should be specific for certain cancer types. For human and microbe data, we identified features that recurrently ranked as the top 500 most important. Among these recurrent features, for each cancer type, human genes and microbe genera with the greatest fold changes (compared to the remaining cancer types) are illustrated (<xref ref-type="fig" rid="fig5">Figure 5D</xref>, <xref ref-type="fig" rid="fig5">Figure 5E</xref>).</p><p>For human genes, the top features for colorectal cancer and stomach cancer are mainly circRNAs. Several cfRNAs specific to liver cancer are genes known to be specifically expressed in the liver (TF, HRG, CP, and FGA) (<xref ref-type="bibr" rid="bib32">Liu et al., 2008</xref>). The lung cancer-specific cfRNAs IL1R2 and CLEC4E are related to immune regulation (<xref ref-type="bibr" rid="bib46">Patin et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Molgora et al., 2018</xref>).</p><p>To investigate circRNAs that are specifically upregulated in colorectal cancer and stomach cancer more systematically, we analyzed mioncocirc (<xref ref-type="bibr" rid="bib65">Vo et al., 2019</xref>) data and ranked circRNAs according to fold change between tumor and normal tissue, followed by gene set enrichment analysis (GSEA) using circRNA specifically upregulated. In both cancer types, we found mild but significant enrichment (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>), suggesting that a subset of circRNAs upregulated in primary cancer tissue sites may enter the circulatory system and contribute to the plasma cfRNA pool.</p><p>Regarding microbial features (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), <italic>Mycoplasma</italic> and <italic>Acholeplasma</italic> were identified as colorectal cancer specific in our cfRNA profiles. The relevance between <italic>Mycoplasma</italic> infection and cancers was previously reported (<xref ref-type="bibr" rid="bib18">Huang et al., 2001</xref>; <xref ref-type="bibr" rid="bib74">Zella et al., 2018</xref>). <italic>Acholeplasma</italic> was also reported to be more abundant in the gut microbiome of colon cancer patients (<xref ref-type="bibr" rid="bib59">Shoji et al., 2021</xref>). The stomach cancer specific genus <italic>Noviherbaspirillum</italic> was reported to be enriched in oral cancer patients (<xref ref-type="bibr" rid="bib55">Sarkar et al., 2021</xref>). Consistently, <italic>Orthohepadnavirus</italic> and TTVs were again identified as liver cancer specific. <italic>Erysipelatoclostridium</italic>, for which cfRNA is more abundant in the plasma of esophageal cancer patients, is related to several human intestinal diseases (<xref ref-type="bibr" rid="bib55">Sarkar et al., 2021</xref>; <xref ref-type="bibr" rid="bib35">Mancabelli et al., 2017</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we sequenced cfRNAs in a cohort of patients with five major types of highly malignant cancer. We demonstrated that there are biologically relevant differences between the cfRNAs of HDs and cancer patients. Cancer type-specific signals could be identified in both human and microbial cfRNAs, and these signals could be utilized to detect and classify multiple cancers, including early-stage cases.</p><p>The existence of microbe-derived plasma nucleic acids in donors without sepsis has been independently demonstrated by multiple studies. In typical bioinformatic analysis, reads that cannot be aligned to the human genome are discarded. Our work suggests that these data can be further exploited and provide useful information for microbial profiling in plasma. Several studies have demonstrated that the human virome at different body sites, including plasma, has an unexpected diversity (<xref ref-type="bibr" rid="bib23">Kowarsky et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Liang and Bushman, 2021</xref>), and current knowledge of human-associated viruses is largely limited to species that could cause severe clinical consequences. Our work highlights the feasibility of discovering clinically relevant but understudied viruses from high-throughput sequencing data.</p><p>There are complicated interactions between tumor, the tumor microenvironment, human-associated microbes, and the circulatory system. Tumors with different primary locations have distinct transcriptome compositions and can induce tumor type-specific alterations in other cells or cell fragments, such as TEPs (<xref ref-type="bibr" rid="bib4">Best et al., 2015</xref>). Tumor cells, microbes, and other cells that carry tumor-induced transcriptome alterations all contribute to the cfRNA pool and produce detectable cancer type-specific signals. It is expected that their relative contributions vary in different cancer types. In liver cancer, the identified tumor site-specific features (liver-specific genes and well-known viruses) are readily interpretable. The remaining ones can potentially be explained by the greater contribution of secondary signals that reflect tumor-induced alterations in certain blood components and uncharacterized interactions between humans and microbes. circRNAs have been proposed as exosome-based cancer biomarkers (<xref ref-type="bibr" rid="bib29">Li et al., 2015</xref>). In this study, several plasma circRNAs with cancer type specificity for colorectal and stomach cancer were identified. For colorectal and stomach cancer, the enrichment of upregulated plasma circRNAs suggests that changes in the abundance of plasma circRNAs mirror a subset of circRNA alterations in tumor tissues.</p><p>Currently, various cfDNA features (e.g. fragment size, end motif, and methylation) have been well applied to liquid biopsy (<xref ref-type="bibr" rid="bib33">Lo et al., 2021</xref>). Meanwhile, cfRNA provides its own advantages (<xref ref-type="bibr" rid="bib10">Dolgin, 2020</xref>). First, compared to DNAs, many RNAs are more actively transported outside of the cell through carriers such as exosomes; and some cfRNAs, such as the srpRNA RN7SL2, were reported to play regulatory rules in the cancer microenvironment (<xref ref-type="bibr" rid="bib41">Nabet et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Johnson et al., 2021</xref>). As a result, cfRNA-based biomarkers may provide more functional insights. In addition, RNA expression is tissue-specific; given the dramatic changes in the RNA expression profile in tumors, a fraction of these alterations could be reflected in plasma. Furthermore, the long cfRNA sequencing used in this study detects mRNA of both DNA and RNA viruses, while neither DNA-seq nor small cfRNA-seq can. It has been reported that microbe-derived cfDNA only makes up a small fraction (lower than 0.5% in some cases) of plasma cfDNA (<xref ref-type="bibr" rid="bib76">Zozaya-Valdés et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Kowarsky et al., 2017</xref>; <xref ref-type="bibr" rid="bib69">Xiao et al., 2021b</xref>). The genomes of bacteria and viruses are much more compact than the human genome, and a larger fraction of their genome sequences are transcribed into RNAs. This indicates that if mixtures of human cells and microbes are sequenced by DNA-seq and RNA-seq to the same depth, microbial reads should make up a larger fraction (approximately 10% on average in our study) in the RNA-seq library, and their signals can be captured more cost-effectively. For these reasons, we believe cfRNA-seq is a cost-effective alternative to cfDNA sequencing, which provides complementary information.</p><p>The confounding effect is a major obstacle for discovering reliable biomarkers from high-throughput data. In our cohort design, samples were collected from different clinical centers, and sex for certain cancer types, such as liver cancer, was not well balanced. We attempted to mitigate the problems computationally by using RUVg to remove these unwanted variations. Our analysis provided clues for the clinical relevance of microbe-derived cfRNAs, but a study with a larger, carefully designed cohort is still necessary for clinical application.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cohort design and sample collection</title><p>The cohort in this study included 295 plasma samples in total. Except for 65 previously published samples (GSE142987: 35 liver cancer patients and 30 HDs; <xref ref-type="bibr" rid="bib75">Zhu et al., 2021</xref>), we sequenced the total cfRNAs (&gt;50 nt) in 230 additional plasma samples (54 colorectal cancer, 37 stomach cancer, 27 liver cancer, 35 lung cancer, 31 esophageal cancer, and 46 HDs). The criteria for inclusion were pathologically diagnosed colorectal cancer, stomach cancer, liver cancer, lung cancer, and esophageal cancer patients before surgery, radiation, and chemotherapy.</p><p>Samples were obtained between October 2018 and January 2020 from six clinical centers in China: Peking University First Hospital (PKU, Beijing), Peking Union Medical College Hospital (PUMCH, Beijing), Department of Epidemiology Navy Medical University (ShH-1, Shanghai), Eastern Hepatobiliary Surgery Hospital (ShH-2, Shanghai), National Center for Liver Cancer (ShH-3, Shanghai), and Southwest Hospital (SWU, Chongqing). The study was approved by the Peking University First Hospital Biomedical Research Ethics Committee (2018Y15) complied with the declaration of Helsinki. Written informed consent was obtained from all patients prior to the enrollment of this study.</p><p>Peripheral whole blood samples were collected from participants before therapy using EDTA-coated vacutainer tubes. The tubes were inverted 8–10 times to mix the blood with anticoagulant. Plasma was separated by a standard clinical blood centrifugation protocol within 2 hr after collection. All plasma samples were aliquoted and stored at –80°C before cfRNA extraction.</p></sec><sec id="s4-2"><title>cfRNA-seq library preparation</title><p>cfRNAs were extracted from 1 mL of plasma using the Plasma/Serum Circulating RNA and Exosomal Purification kit (Norgen). Purification was based on the use of Norgen’s proprietary resin as the separation matrix. This kit extracts all sizes of circulating cfRNAs. The concentration of extracted cfRNAs was assessed using the Qubit RNA assay (Life Technologies).</p><p>The total cfRNA library (&gt;50 nt) was prepared with the SMARTer Stranded Total RNA-Seq Kit–Pico. This kit removes ribosomal cDNAs after reverse transcription using a CRISPR/DASH method. We used recombinant DNase I (TAKARA) to digest circulating DNA. ERCC RNA Spike-In Control Mixes (Ambion) were added to the samples before library preparation, with 1 μL per library at an appropriate concentration. RNA Clean and Concentrator-5 kit (Zymo) was used to obtain purified total RNA. More than 20 million reads of total cfRNA were sequenced on an Illumina platform for each library.</p><p>Potential contamination in RNA extraction and library preparation was evaluated using two types of negative controls. Two RNA samples were extracted from the <italic>E. coli</italic> DH5α strain, using the same kit for plasma cfRNA extraction. RNA-seq libraries of <italic>E. coli</italic> RNA samples, together with human brain RNA provided by SMARTer Stranded Total RNA-Seq Kit, were constructed using the same protocol for cfRNA library preparation.</p></sec><sec id="s4-3"><title>Data processing</title><p>For RNA sequencing data, adapters and low-quality sequences in raw sequencing data were trimmed using cutadapt (<xref ref-type="bibr" rid="bib36">Martin, 2011</xref>) (version 2.3). GC oligos introduced in reverse transcription were also trimmed off, and reads shorter than 30 nt were discarded. We used STAR (<xref ref-type="bibr" rid="bib9">Dobin et al., 2013</xref>) (version 2.5.3 a_modified) for sequence mapping. The trimmed reads were sequentially mapped to ERCC’s spike-in sequences, vector sequences in NCBI’s UniVec database, and human rRNA sequences in RefSeq annotation.</p><p>The remaining reads were mapped to the hg38 genome index built with the GENCODE (<xref ref-type="bibr" rid="bib17">Harrow et al., 2012</xref>) v27 annotation. circRNA annotation was downloaded from circBase (<xref ref-type="bibr" rid="bib12">Glažar et al., 2014</xref>). Upstream 150 bp and downstream 150 bp sequences around the back-spliced sites of circRNAs were concatenated to generate junction sequences, and circRNA sequences shorter than 100 bp were discarded. Reads unaligned to hg38 were mapped to circRNA junctions. Duplicates in the aligned reads were removed using Picard Tools MarkDuplicates (version 2.20.0). An aligned read pair was assigned to an RNA type if at least one of the mates overlapped with the corresponding genomic regions. In this way, the aligned reads were sequentially assigned to lncRNAs, mRNAs, snoRNAs, snRNAs, srpRNAs, and Y RNAs with HTSeq (<xref ref-type="bibr" rid="bib2">Anders et al., 2015</xref>) package according to the GENCODE v27 annotation.</p><p>The count matrix for human genes was constructed using featureCounts (<xref ref-type="bibr" rid="bib31">Liao et al., 2014</xref>) v1.6.2 with the GENCODE v27 annotation. For downstream analysis, we only considered circRNA junctions annotated in both circBase and mioncocirc (<xref ref-type="bibr" rid="bib65">Vo et al., 2019</xref>). To avoid the impact of potential DNA contamination, only intron-spanning reads were considered.</p></sec><sec id="s4-4"><title>Quality control</title><p>We filtered cfRNA-seq samples with multiple quality control criteria (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>): (1) raw reads &gt;10 million; (2) clean reads (reads remained after trimming low quality and adaptor sequences) &gt;5 million; (3) aligned reads after duplicate removal (aligned to the human genome, hg38, and circRNA junctions) &gt;0.5 million; (4) for the clean reads, the fraction of spike-in reads &lt;0.5 and ratio of rRNA reads &lt;0.5; (5) for genome aligned reads, the ratio of mRNA and lncRNA reads &gt;0.2, the ratio of unclassified reads &lt;0.3, and the number of intron-spanning read pairs (defined as a read pair with a CIGAR string in which at least one mate contains ‘N’ in the BAM files) &gt;100,000.</p></sec><sec id="s4-5"><title>Differential analysis and functional enrichment analysis</title><p>We used the quasi-likelihood method in the edgeR (<xref ref-type="bibr" rid="bib53">Robinson et al., 2010</xref>) package to identify differentially expressed genes and genera with significant abundance alterations (|log<sub>2</sub>[fold-change]|&gt;1 and FDR &lt;0.05). We used this method to identify differential genes between cancer patients and HDs, as well as genes specific to one cancer type. For cancer type-specific genes, previously reported gender-related genes (<xref ref-type="bibr" rid="bib58">Shi et al., 2019</xref>) were excluded. KEGG pathway enrichment analysis of deregulated genes/RNAs was carried out using clusterProfiler (<xref ref-type="bibr" rid="bib72">Yu et al., 2012</xref>).</p></sec><sec id="s4-6"><title>Data normalization</title><p>The count matrix of gene expression was normalized using the trimmed mean of M-values (TMM) method in edgeR (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). ANOVA was performed among different sample groups (HD and five cancer types) using the quasi-likelihood method in edgeR, and the 25% most insignificant genes that were stably expressed among different groups were considered as empirical control genes. The TMM normalized expression matrix was adjusted by the RUVg function in the RUVSeq (<xref ref-type="bibr" rid="bib52">Risso et al., 2014</xref>) package based on the identified control features.</p></sec><sec id="s4-7"><title>Microbial data analysis</title><p>Unmapped reads (cleaned reads that failed to align to the human genome or circRNA junctions) were processed independently using a k-mer-based pipeline and an alignment-based pipeline. In the first pipeline, unmapped reads were classified using kraken2 (<xref ref-type="bibr" rid="bib67">Wood et al., 2019</xref>) with its standard database, which contains bacterial, archaeal, viral, and human sequences. In the alignment-based pipeline, using SortMeRNA (<xref ref-type="bibr" rid="bib21">Kopylova et al., 2012</xref>) (version 4.3.3), unmapped reads were annotated as either rRNA or non-rRNA. rRNA reads were mapped to the Silva database with bowtie (<xref ref-type="bibr" rid="bib24">Langmead and Salzberg, 2012</xref>). Non-rRNA reads were aligned to the virus genome curated in kraken2’s standard database. In both pipelines, counts at the genus level were used for downstream analysis.</p><p>The same preprocessing and downstream analysis pipeline were applied to negative control samples (<italic>E. coli</italic> RNA-seq data were aligned to the reference genome NZ_CP025520.1 with bowtie2, instead of map to human rRNA, human genome, and circRNA junctions). For read coverage analysis of <italic>L. clevelandensis</italic> and HBV, reads unmapped to human sequences were mapped to their reference genomes (NZ_CP012390.1 and NC_003977.2, respectively).</p><p>Potential contaminations in genera detected by both the kraken2 pipeline and bowtie2 pipeline (with at least three reads in at least three samples) were filtered prior to downstream analysis. We removed bacterial genera detected in at least one control sample (at least three reads) and virus genera detected in at least one <italic>E. coli</italic> control sample (at least three reads). Genera present in a previously reported common laboratory contamination list (<xref ref-type="bibr" rid="bib54">Salter et al., 2014</xref>) or genera that contain species with counts per million &gt;10 in a published human skin microbiome dataset (<xref ref-type="bibr" rid="bib43">Oh et al., 2016</xref>) were removed. Virus genera that contain species with nonhuman eukaryotic hosts according to virushostdb (<xref ref-type="bibr" rid="bib37">Mihara et al., 2016</xref>) were also excluded. The genera with altered abundance were identified using edgeR. Counts at the genus level were also normalized with TMM and RUVg, as we did for human gene expression.</p></sec><sec id="s4-8"><title>Classification performance evaluation</title><p>We evaluated the discriminative capacity of cfRNA features with bootstrapping. Training instances were sampled from the full dataset until the sample size of the training set reached the original dataset, and the remaining samples were used for performance evaluation. We used this procedure to generate 100 training sets and corresponding testing sets. For each training set, we performed feature filtering with a rank-sum test. To mitigate the impact of within-class heterogeneity, we sampled a 75% subset of the training instances, performed a rank-sum test (implement withed rank-sums functions in scipy <xref ref-type="bibr" rid="bib64">Virtanen et al., 2020</xref>), nd recorded 50 most significant features, repeated this process 10 times, and took the union of all selected features to fit a balanced random forest classifier (implemented in python package imblearn <xref ref-type="bibr" rid="bib28">Lemaître et al., 2017</xref>). The maximum depths of the trees in the random forest were determined by fivefold cross-validation.</p><p>For multiclass classification, a similar bootstrapping strategy was applied. For each of the 100 training-testing pairs, we sampled a 75% subset from the training instances, performed pairwise rank-sum tests, recorded the 50 most significant features, took the union of features selected in different comparisons, repeated this process 10 times, and took the union of all selected features for model fitting.</p></sec><sec id="s4-9"><title>Gene set enrichment analysis</title><p>GSEA was implemented with the fgsea (<xref ref-type="bibr" rid="bib22">Korotkevich et al., 2016</xref>) package. For enrichment analysis of circRNA specifically upregulated in one cancer type, circRNA expression data in tumors and normal tissues were downloaded from the mioncocirc (<xref ref-type="bibr" rid="bib65">Vo et al., 2019</xref>) (<ext-link ext-link-type="uri" xlink:href="https://mioncocirc.github.io/">https://mioncocirc.github.io/</ext-link>) database. For colorectal cancer and esophagus cancer, circRNAs were ranked according to their fold change between tumor and normal tissue, up to 300 circRNAs that were upregulated in one vs. rest comparison with log<sub>2</sub>(fold-change) &gt;0.5, and FDR &lt;0.05 were used for enrichment analysis.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Investigation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology, Validation, Visualization, Writing - original draft</p></fn><fn fn-type="con" id="con5"><p>Resources</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Investigation, Software</p></fn><fn fn-type="con" id="con10"><p>Methodology</p></fn><fn fn-type="con" id="con11"><p>Project administration, Resources</p></fn><fn fn-type="con" id="con12"><p>Resources</p></fn><fn fn-type="con" id="con13"><p>Resources, Validation</p></fn><fn fn-type="con" id="con14"><p>Project administration, Resources, Validation, Visualization</p></fn><fn fn-type="con" id="con15"><p>Resources, Supervision</p></fn><fn fn-type="con" id="con16"><p>Resources, Software, Supervision</p></fn><fn fn-type="con" id="con17"><p>Resources, Supervision, Validation</p></fn><fn fn-type="con" id="con18"><p>Methodology, Resources</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Investigation, Methodology, Project administration, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The study was approved by the Peking University First Hospital Biomedical Research Ethics Committee (2018Y15) complied with the declaration of Helsinki. Written informed consent was obtained from all patients prior to the enrollment of this study.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Clinical information of samples used in this study.</title></caption><media xlink:href="elife-75181-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Statistics in reads mapping.</title></caption><media xlink:href="elife-75181-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Filtering of potential contamination and read counts in negative control samples.</title></caption><media xlink:href="elife-75181-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Fraction of reads assigned to difference sequences.</title></caption><media xlink:href="elife-75181-supp4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Differential analysis for human and microbial reads between cancer patients and healthy donors.</title></caption><media xlink:href="elife-75181-supp5-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Differential analysis for one vs. rest comparisons between different cancer types.</title></caption><media xlink:href="elife-75181-supp6-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>Recurrency and average importance rank of top 100 features for cancer detection.</title></caption><media xlink:href="elife-75181-supp7-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>Recurrency and average importance rank of top 500 features for cancer classification.</title></caption><media xlink:href="elife-75181-supp8-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-75181-transrepform1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Sequencing data have been deposited in GEO under accession codes GSE174302.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Cancer type classification using plasma cell-free RNAs derived from human and microbes</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE174302">GSE174302</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Siqi</surname><given-names>W</given-names></name><name><surname>Zhi</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>RNA-seq analysis of liver cancer patients' plasma</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142987">GSE142987</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the Capital’s Funds for Health Improvement and Research (CFH 2022-2-4075), the National Natural Science Foundation of China (31771461, 3217040246, 81972798, 81373067, 81773140, 81902384), the National Key Research and Development Plan of China (2017YFA0505803, 2017YFC0908401, 2019YFC1315700), the National Science and Technology Major Project of China (2018Z × 10723204, 2018Z × 10302205), the Tsinghua University Initiative Scientific Research Program (2021Z99CFY022), the Tsinghua-Foshan Innovation Special Fund, and the Fok Ying-Tong Education Foundation. This study was also supported by the Interdisciplinary Clinical Research Project of Peking University First Hospital, Beijing Advanced Innovation Center for Structural Biology, and the Bioinformatics Platform of National Center for Protein Sciences (Beijing) [2021-NCPSB-005].</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbosh</surname><given-names>C</given-names></name><name><surname>Birkbak</surname><given-names>NJ</given-names></name><name><surname>Wilson</surname><given-names>GA</given-names></name><name><surname>Jamal-Hanjani</surname><given-names>M</given-names></name><name><surname>Constantin</surname><given-names>T</given-names></name><name><surname>Salari</surname><given-names>R</given-names></name><name><surname>Le Quesne</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>DA</given-names></name><name><surname>Veeriah</surname><given-names>S</given-names></name><name><surname>Rosenthal</surname><given-names>R</given-names></name><name><surname>Marafioti</surname><given-names>T</given-names></name><name><surname>Kirkizlar</surname><given-names>E</given-names></name><name><surname>Watkins</surname><given-names>TBK</given-names></name><name><surname>McGranahan</surname><given-names>N</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Martinson</surname><given-names>L</given-names></name><name><surname>Riley</surname><given-names>J</given-names></name><name><surname>Fraioli</surname><given-names>F</given-names></name><name><surname>Al Bakir</surname><given-names>M</given-names></name><name><surname>Grönroos</surname><given-names>E</given-names></name><name><surname>Zambrana</surname><given-names>F</given-names></name><name><surname>Endozo</surname><given-names>R</given-names></name><name><surname>Bi</surname><given-names>WL</given-names></name><name><surname>Fennessy</surname><given-names>FM</given-names></name><name><surname>Sponer</surname><given-names>N</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Laycock</surname><given-names>J</given-names></name><name><surname>Shafi</surname><given-names>S</given-names></name><name><surname>Czyzewska-Khan</surname><given-names>J</given-names></name><name><surname>Rowan</surname><given-names>A</given-names></name><name><surname>Chambers</surname><given-names>T</given-names></name><name><surname>Matthews</surname><given-names>N</given-names></name><name><surname>Turajlic</surname><given-names>S</given-names></name><name><surname>Hiley</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Forster</surname><given-names>MD</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Falzon</surname><given-names>M</given-names></name><name><surname>Borg</surname><given-names>E</given-names></name><name><surname>Lawrence</surname><given-names>D</given-names></name><name><surname>Hayward</surname><given-names>M</given-names></name><name><surname>Kolvekar</surname><given-names>S</given-names></name><name><surname>Panagiotopoulos</surname><given-names>N</given-names></name><name><surname>Janes</surname><given-names>SM</given-names></name><name><surname>Thakrar</surname><given-names>R</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Blackhall</surname><given-names>F</given-names></name><name><surname>Summers</surname><given-names>Y</given-names></name><name><surname>Hafez</surname><given-names>D</given-names></name><name><surname>Naik</surname><given-names>A</given-names></name><name><surname>Ganguly</surname><given-names>A</given-names></name><name><surname>Kareht</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><name><surname>Marie Quinn</surname><given-names>A</given-names></name><name><surname>Crosbie</surname><given-names>PA</given-names></name><name><surname>Naidu</surname><given-names>B</given-names></name><name><surname>Middleton</surname><given-names>G</given-names></name><name><surname>Langman</surname><given-names>G</given-names></name><name><surname>Trotter</surname><given-names>S</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Remmen</surname><given-names>H</given-names></name><name><surname>Kerr</surname><given-names>K</given-names></name><name><surname>Chetty</surname><given-names>M</given-names></name><name><surname>Gomersall</surname><given-names>L</given-names></name><name><surname>Fennell</surname><given-names>DA</given-names></name><name><surname>Nakas</surname><given-names>A</given-names></name><name><surname>Rathinam</surname><given-names>S</given-names></name><name><surname>Anand</surname><given-names>G</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Russell</surname><given-names>P</given-names></name><name><surname>Ezhil</surname><given-names>V</given-names></name><name><surname>Ismail</surname><given-names>B</given-names></name><name><surname>Irvin-Sellers</surname><given-names>M</given-names></name><name><surname>Prakash</surname><given-names>V</given-names></name><name><surname>Lester</surname><given-names>JF</given-names></name><name><surname>Kornaszewska</surname><given-names>M</given-names></name><name><surname>Attanoos</surname><given-names>R</given-names></name><name><surname>Adams</surname><given-names>H</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Oukrif</surname><given-names>D</given-names></name><name><surname>Akarca</surname><given-names>AU</given-names></name><name><surname>Hartley</surname><given-names>JA</given-names></name><name><surname>Lowe</surname><given-names>HL</given-names></name><name><surname>Lock</surname><given-names>S</given-names></name><name><surname>Iles</surname><given-names>N</given-names></name><name><surname>Bell</surname><given-names>H</given-names></name><name><surname>Ngai</surname><given-names>Y</given-names></name><name><surname>Elgar</surname><given-names>G</given-names></name><name><surname>Szallasi</surname><given-names>Z</given-names></name><name><surname>Schwarz</surname><given-names>RF</given-names></name><name><surname>Herrero</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Quezada</surname><given-names>SA</given-names></name><name><surname>Peggs</surname><given-names>KS</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Dive</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>CJ</given-names></name><name><surname>Rabinowitz</surname><given-names>M</given-names></name><name><surname>Aerts</surname><given-names>HJWL</given-names></name><name><surname>Hackshaw</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>JA</given-names></name><name><surname>Zimmermann</surname><given-names>BG</given-names></name><collab>TRACERx consortium</collab><collab>PEACE consortium</collab><name><surname>Swanton</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution</article-title><source>Nature</source><volume>545</volume><fpage>446</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1038/nature22364</pub-id><pub-id pub-id-type="pmid">28445469</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Pyl</surname><given-names>PT</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HTSeq--a Python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics (Oxford, England)</source><volume>31</volume><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id><pub-id pub-id-type="pmid">25260700</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arbuthnot</surname><given-names>P</given-names></name><name><surname>Kew</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Hepatitis B virus and hepatocellular carcinoma</article-title><source>International Journal of Experimental Pathology</source><volume>82</volume><fpage>77</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2613.2001.iep0082-0077-x</pub-id><pub-id pub-id-type="pmid">11454100</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>MG</given-names></name><name><surname>Sol</surname><given-names>N</given-names></name><name><surname>Kooi</surname><given-names>I</given-names></name><name><surname>Tannous</surname><given-names>J</given-names></name><name><surname>Westerman</surname><given-names>BA</given-names></name><name><surname>Rustenburg</surname><given-names>F</given-names></name><name><surname>Schellen</surname><given-names>P</given-names></name><name><surname>Verschueren</surname><given-names>H</given-names></name><name><surname>Post</surname><given-names>E</given-names></name><name><surname>Koster</surname><given-names>J</given-names></name><name><surname>Ylstra</surname><given-names>B</given-names></name><name><surname>Ameziane</surname><given-names>N</given-names></name><name><surname>Dorsman</surname><given-names>J</given-names></name><name><surname>Smit</surname><given-names>EF</given-names></name><name><surname>Verheul</surname><given-names>HM</given-names></name><name><surname>Noske</surname><given-names>DP</given-names></name><name><surname>Reijneveld</surname><given-names>JC</given-names></name><name><surname>Nilsson</surname><given-names>RJA</given-names></name><name><surname>Tannous</surname><given-names>BA</given-names></name><name><surname>Wesseling</surname><given-names>P</given-names></name><name><surname>Wurdinger</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics</article-title><source>Cancer Cell</source><volume>28</volume><fpage>666</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.09.018</pub-id><pub-id pub-id-type="pmid">26525104</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blauwkamp</surname><given-names>TA</given-names></name><name><surname>Thair</surname><given-names>S</given-names></name><name><surname>Rosen</surname><given-names>MJ</given-names></name><name><surname>Blair</surname><given-names>L</given-names></name><name><surname>Lindner</surname><given-names>MS</given-names></name><name><surname>Vilfan</surname><given-names>ID</given-names></name><name><surname>Kawli</surname><given-names>T</given-names></name><name><surname>Christians</surname><given-names>FC</given-names></name><name><surname>Venkatasubrahmanyam</surname><given-names>S</given-names></name><name><surname>Wall</surname><given-names>GD</given-names></name><name><surname>Cheung</surname><given-names>A</given-names></name><name><surname>Rogers</surname><given-names>ZN</given-names></name><name><surname>Meshulam-Simon</surname><given-names>G</given-names></name><name><surname>Huijse</surname><given-names>L</given-names></name><name><surname>Balakrishnan</surname><given-names>S</given-names></name><name><surname>Quinn</surname><given-names>JV</given-names></name><name><surname>Hollemon</surname><given-names>D</given-names></name><name><surname>Hong</surname><given-names>DK</given-names></name><name><surname>Vaughn</surname><given-names>ML</given-names></name><name><surname>Kertesz</surname><given-names>M</given-names></name><name><surname>Bercovici</surname><given-names>S</given-names></name><name><surname>Wilber</surname><given-names>JC</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease</article-title><source>Nature Microbiology</source><volume>4</volume><fpage>663</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0349-6</pub-id><pub-id pub-id-type="pmid">30742071</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burd</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Human papillomavirus and cervical cancer</article-title><source>Clinical Microbiology Reviews</source><volume>16</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1128/CMR.16.1.1-17.2003</pub-id><pub-id pub-id-type="pmid">12525422</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristiano</surname><given-names>S</given-names></name><name><surname>Leal</surname><given-names>A</given-names></name><name><surname>Phallen</surname><given-names>J</given-names></name><name><surname>Fiksel</surname><given-names>J</given-names></name><name><surname>Adleff</surname><given-names>V</given-names></name><name><surname>Bruhm</surname><given-names>DC</given-names></name><name><surname>Jensen</surname><given-names>SØ</given-names></name><name><surname>Medina</surname><given-names>JE</given-names></name><name><surname>Hruban</surname><given-names>C</given-names></name><name><surname>White</surname><given-names>JR</given-names></name><name><surname>Palsgrove</surname><given-names>DN</given-names></name><name><surname>Niknafs</surname><given-names>N</given-names></name><name><surname>Anagnostou</surname><given-names>V</given-names></name><name><surname>Forde</surname><given-names>P</given-names></name><name><surname>Naidoo</surname><given-names>J</given-names></name><name><surname>Marrone</surname><given-names>K</given-names></name><name><surname>Brahmer</surname><given-names>J</given-names></name><name><surname>Woodward</surname><given-names>BD</given-names></name><name><surname>Husain</surname><given-names>H</given-names></name><name><surname>van Rooijen</surname><given-names>KL</given-names></name><name><surname>Ørntoft</surname><given-names>M-BW</given-names></name><name><surname>Madsen</surname><given-names>AH</given-names></name><name><surname>van de Velde</surname><given-names>CJH</given-names></name><name><surname>Verheij</surname><given-names>M</given-names></name><name><surname>Cats</surname><given-names>A</given-names></name><name><surname>Punt</surname><given-names>CJA</given-names></name><name><surname>Vink</surname><given-names>GR</given-names></name><name><surname>van Grieken</surname><given-names>NCT</given-names></name><name><surname>Koopman</surname><given-names>M</given-names></name><name><surname>Fijneman</surname><given-names>RJA</given-names></name><name><surname>Johansen</surname><given-names>JS</given-names></name><name><surname>Nielsen</surname><given-names>HJ</given-names></name><name><surname>Meijer</surname><given-names>GA</given-names></name><name><surname>Andersen</surname><given-names>CL</given-names></name><name><surname>Scharpf</surname><given-names>RB</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genome-wide cell-free DNA fragmentation in patients with cancer</article-title><source>Nature</source><volume>570</volume><fpage>385</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1272-6</pub-id><pub-id pub-id-type="pmid">31142840</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vlaminck</surname><given-names>I</given-names></name><name><surname>Khush</surname><given-names>KK</given-names></name><name><surname>Strehl</surname><given-names>C</given-names></name><name><surname>Kohli</surname><given-names>B</given-names></name><name><surname>Luikart</surname><given-names>H</given-names></name><name><surname>Neff</surname><given-names>NF</given-names></name><name><surname>Okamoto</surname><given-names>J</given-names></name><name><surname>Snyder</surname><given-names>TM</given-names></name><name><surname>Cornfield</surname><given-names>DN</given-names></name><name><surname>Nicolls</surname><given-names>MR</given-names></name><name><surname>Weill</surname><given-names>D</given-names></name><name><surname>Bernstein</surname><given-names>D</given-names></name><name><surname>Valantine</surname><given-names>HA</given-names></name><name><surname>Quake</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Temporal response of the human virome to immunosuppression and antiviral therapy</article-title><source>Cell</source><volume>155</volume><fpage>1178</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.10.034</pub-id><pub-id pub-id-type="pmid">24267896</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics (Oxford, England)</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolgin</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Putting extracellular RNA to the diagnostic test</article-title><source>Nature</source><volume>582</volume><fpage>S2</fpage><lpage>S4</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-01763-1</pub-id><pub-id pub-id-type="pmid">32555473</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenhofer</surname><given-names>R</given-names></name><name><surname>Minich</surname><given-names>JJ</given-names></name><name><surname>Marotz</surname><given-names>C</given-names></name><name><surname>Cooper</surname><given-names>A</given-names></name><name><surname>Knight</surname><given-names>R</given-names></name><name><surname>Weyrich</surname><given-names>LS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Contamination in Low Microbial Biomass Microbiome Studies: Issues and Recommendations</article-title><source>Trends in Microbiology</source><volume>27</volume><fpage>105</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2018.11.003</pub-id><pub-id pub-id-type="pmid">30497919</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glažar</surname><given-names>P</given-names></name><name><surname>Papavasileiou</surname><given-names>P</given-names></name><name><surname>Rajewsky</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>circBase: a database for circular RNAs</article-title><source>RNA (New York, N.Y.)</source><volume>20</volume><fpage>1666</fpage><lpage>1670</lpage><pub-id pub-id-type="doi">10.1261/rna.043687.113</pub-id><pub-id pub-id-type="pmid">25234927</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldenberger</surname><given-names>D</given-names></name><name><surname>Naegele</surname><given-names>M</given-names></name><name><surname>Steffens</surname><given-names>D</given-names></name><name><surname>Eichenberger</surname><given-names>R</given-names></name><name><surname>Egli</surname><given-names>A</given-names></name><name><surname>Seth-Smith</surname><given-names>HMB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Emerging anaerobic and partially acid-fast Lawsonella clevelandensis: extended characterization by antimicrobial susceptibility testing and whole genome sequencing</article-title><source>Clinical Microbiology and Infection</source><volume>25</volume><fpage>1447</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2019.07.008</pub-id><pub-id pub-id-type="pmid">31306789</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosiewski</surname><given-names>T</given-names></name><name><surname>Ludwig-Galezowska</surname><given-names>AH</given-names></name><name><surname>Huminska</surname><given-names>K</given-names></name><name><surname>Sroka-Oleksiak</surname><given-names>A</given-names></name><name><surname>Radkowski</surname><given-names>P</given-names></name><name><surname>Salamon</surname><given-names>D</given-names></name><name><surname>Wojciechowicz</surname><given-names>J</given-names></name><name><surname>Kus-Slowinska</surname><given-names>M</given-names></name><name><surname>Bulanda</surname><given-names>M</given-names></name><name><surname>Wolkow</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Comprehensive detection and identification of bacterial DNA in the blood of patients with sepsis and healthy volunteers using next-generation sequencing method - the observation of DNAemia</article-title><source>European Journal of Clinical Microbiology &amp; Infectious Diseases</source><volume>36</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1007/s10096-016-2805-7</pub-id><pub-id pub-id-type="pmid">27771780</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Crawford</surname><given-names>ED</given-names></name><name><surname>O’Donovan</surname><given-names>BD</given-names></name><name><surname>Wilson</surname><given-names>MR</given-names></name><name><surname>Chow</surname><given-names>ED</given-names></name><name><surname>Retallack</surname><given-names>H</given-names></name><name><surname>DeRisi</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove unwanted high-abundance species in sequencing libraries and molecular counting applications</article-title><source>Genome Biology</source><volume>17</volume><elocation-id>41</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-0904-5</pub-id><pub-id pub-id-type="pmid">26944702</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>YW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fusobacterium nucleatum: a commensal-turned pathogen</article-title><source>Current Opinion in Microbiology</source><volume>23</volume><fpage>141</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2014.11.013</pub-id><pub-id pub-id-type="pmid">25576662</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrow</surname><given-names>J</given-names></name><name><surname>Frankish</surname><given-names>A</given-names></name><name><surname>Gonzalez</surname><given-names>JM</given-names></name><name><surname>Tapanari</surname><given-names>E</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><name><surname>Kokocinski</surname><given-names>F</given-names></name><name><surname>Aken</surname><given-names>BL</given-names></name><name><surname>Barrell</surname><given-names>D</given-names></name><name><surname>Zadissa</surname><given-names>A</given-names></name><name><surname>Searle</surname><given-names>S</given-names></name><name><surname>Barnes</surname><given-names>I</given-names></name><name><surname>Bignell</surname><given-names>A</given-names></name><name><surname>Boychenko</surname><given-names>V</given-names></name><name><surname>Hunt</surname><given-names>T</given-names></name><name><surname>Kay</surname><given-names>M</given-names></name><name><surname>Mukherjee</surname><given-names>G</given-names></name><name><surname>Rajan</surname><given-names>J</given-names></name><name><surname>Despacio-Reyes</surname><given-names>G</given-names></name><name><surname>Saunders</surname><given-names>G</given-names></name><name><surname>Steward</surname><given-names>C</given-names></name><name><surname>Harte</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Howald</surname><given-names>C</given-names></name><name><surname>Tanzer</surname><given-names>A</given-names></name><name><surname>Derrien</surname><given-names>T</given-names></name><name><surname>Chrast</surname><given-names>J</given-names></name><name><surname>Walters</surname><given-names>N</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Pei</surname><given-names>B</given-names></name><name><surname>Tress</surname><given-names>M</given-names></name><name><surname>Rodriguez</surname><given-names>JM</given-names></name><name><surname>Ezkurdia</surname><given-names>I</given-names></name><name><surname>van Baren</surname><given-names>J</given-names></name><name><surname>Brent</surname><given-names>M</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Valencia</surname><given-names>A</given-names></name><name><surname>Reymond</surname><given-names>A</given-names></name><name><surname>Gerstein</surname><given-names>M</given-names></name><name><surname>Guigó</surname><given-names>R</given-names></name><name><surname>Hubbard</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>GENCODE: the reference human genome annotation for The ENCODE Project</article-title><source>Genome Research</source><volume>22</volume><fpage>1760</fpage><lpage>1774</lpage><pub-id pub-id-type="doi">10.1101/gr.135350.111</pub-id><pub-id pub-id-type="pmid">22955987</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Shou</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Mycoplasma infections and different human carcinomas</article-title><source>World Journal of Gastroenterology</source><volume>7</volume><fpage>266</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.3748/wjg.v7.i2.266</pub-id><pub-id pub-id-type="pmid">11819772</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaksch</surname><given-names>P</given-names></name><name><surname>Kundi</surname><given-names>M</given-names></name><name><surname>Görzer</surname><given-names>I</given-names></name><name><surname>Muraközy</surname><given-names>G</given-names></name><name><surname>Lambers</surname><given-names>C</given-names></name><name><surname>Benazzo</surname><given-names>A</given-names></name><name><surname>Hoetzenecker</surname><given-names>K</given-names></name><name><surname>Klepetko</surname><given-names>W</given-names></name><name><surname>Puchhammer-Stöckl</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Torque Teno Virus as a Novel Biomarker Targeting the Efficacy of Immunosuppression After Lung Transplantation</article-title><source>The Journal of Infectious Diseases</source><volume>218</volume><fpage>1922</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy452</pub-id><pub-id pub-id-type="pmid">30053048</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>LR</given-names></name><name><surname>Lee</surname><given-names>DY</given-names></name><name><surname>Eacret</surname><given-names>JS</given-names></name><name><surname>Ye</surname><given-names>D</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Minn</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function</article-title><source>Cell</source><volume>184</volume><fpage>4981</fpage><lpage>4995</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.08.004</pub-id><pub-id pub-id-type="pmid">34464586</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopylova</surname><given-names>E</given-names></name><name><surname>Noé</surname><given-names>L</given-names></name><name><surname>Touzet</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data</article-title><source>Bioinformatics (Oxford, England)</source><volume>28</volume><fpage>3211</fpage><lpage>3217</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts611</pub-id><pub-id pub-id-type="pmid">23071270</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Korotkevich</surname><given-names>G</given-names></name><name><surname>Sukhov</surname><given-names>V</given-names></name><name><surname>Budin</surname><given-names>N</given-names></name><name><surname>Shpak</surname><given-names>B</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Sergushichev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fast Gene Set Enrichment Analysis</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/060012</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowarsky</surname><given-names>M</given-names></name><name><surname>Camunas-Soler</surname><given-names>J</given-names></name><name><surname>Kertesz</surname><given-names>M</given-names></name><name><surname>De Vlaminck</surname><given-names>I</given-names></name><name><surname>Koh</surname><given-names>W</given-names></name><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Neff</surname><given-names>NF</given-names></name><name><surname>Okamoto</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>RJ</given-names></name><name><surname>Kharbanda</surname><given-names>S</given-names></name><name><surname>El-Sayed</surname><given-names>Y</given-names></name><name><surname>Blumenfeld</surname><given-names>Y</given-names></name><name><surname>Stevenson</surname><given-names>DK</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Wolfe</surname><given-names>ND</given-names></name><name><surname>Quake</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Numerous uncharacterized and highly divergent microbes which colonize humans are revealed by circulating cell-free DNA</article-title><source>PNAS</source><volume>114</volume><fpage>9623</fpage><lpage>9628</lpage><pub-id pub-id-type="doi">10.1073/pnas.1707009114</pub-id><pub-id pub-id-type="pmid">28830999</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fast gapped-read alignment with Bowtie 2</article-title><source>Nature Methods</source><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larson</surname><given-names>MH</given-names></name><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Mauntz</surname><given-names>RE</given-names></name><name><surname>Stuart</surname><given-names>SM</given-names></name><name><surname>Pimentel</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Knudsgaard</surname><given-names>P</given-names></name><name><surname>Demas</surname><given-names>V</given-names></name><name><surname>Aravanis</surname><given-names>AM</given-names></name><name><surname>Jamshidi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>2357</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-22444-1</pub-id><pub-id pub-id-type="pmid">33883548</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J-S</given-names></name><name><surname>Kim</surname><given-names>M-Y</given-names></name><name><surname>Park</surname><given-names>E-R</given-names></name><name><surname>Shen</surname><given-names>YN</given-names></name><name><surname>Jeon</surname><given-names>J-Y</given-names></name><name><surname>Cho</surname><given-names>E-H</given-names></name><name><surname>Park</surname><given-names>S-H</given-names></name><name><surname>Han</surname><given-names>CJ</given-names></name><name><surname>Choi</surname><given-names>DW</given-names></name><name><surname>Jang</surname><given-names>JJ</given-names></name><name><surname>Suh</surname><given-names>K-S</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SB</given-names></name><name><surname>Lee</surname><given-names>K-H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TMEM165, a Golgi transmembrane protein, is a novel marker for hepatocellular carcinoma and its depletion impairs invasion activity</article-title><source>Oncology Reports</source><volume>40</volume><fpage>1297</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.3892/or.2018.6565</pub-id><pub-id pub-id-type="pmid">30015898</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelouvier</surname><given-names>B</given-names></name><name><surname>Servant</surname><given-names>F</given-names></name><name><surname>Païssé</surname><given-names>S</given-names></name><name><surname>Brunet</surname><given-names>A-C</given-names></name><name><surname>Benyahya</surname><given-names>S</given-names></name><name><surname>Serino</surname><given-names>M</given-names></name><name><surname>Valle</surname><given-names>C</given-names></name><name><surname>Ortiz</surname><given-names>MR</given-names></name><name><surname>Puig</surname><given-names>J</given-names></name><name><surname>Courtney</surname><given-names>M</given-names></name><name><surname>Federici</surname><given-names>M</given-names></name><name><surname>Fernández-Real</surname><given-names>J-M</given-names></name><name><surname>Burcelin</surname><given-names>R</given-names></name><name><surname>Amar</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis</article-title><source>Hepatology (Baltimore, Md.)</source><volume>64</volume><fpage>2015</fpage><lpage>2027</lpage><pub-id pub-id-type="doi">10.1002/hep.28829</pub-id><pub-id pub-id-type="pmid">27639192</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemaître</surname><given-names>G</given-names></name><name><surname>Nogueira</surname><given-names>F</given-names></name><name><surname>Aridas</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Imbalanced-learn: A Python Toolbox to Tackle the Curse of Imbalanced Datasets in Machine Learning</article-title><source>Journal of Machine Learning Research</source><volume>18</volume><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis</article-title><source>Cell Research</source><volume>25</volume><fpage>981</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1038/cr.2015.82</pub-id><pub-id pub-id-type="pmid">26138677</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Bushman</surname><given-names>FD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The human virome: assembly, composition and host interactions</article-title><source>Nature Reviews. Microbiology</source><volume>19</volume><fpage>514</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00536-5</pub-id><pub-id pub-id-type="pmid">33785903</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics (Oxford, England)</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Zack</surname><given-names>DJ</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TiGER: A database for tissue-specific gene expression and regulation</article-title><source>BMC Bioinformatics</source><volume>9</volume><elocation-id>271</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-9-271</pub-id><pub-id pub-id-type="pmid">18541026</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>YMD</given-names></name><name><surname>Han</surname><given-names>DSC</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Chiu</surname><given-names>RWK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies</article-title><source>Science (New York, N.Y.)</source><volume>372</volume><elocation-id>eaaw3616</elocation-id><pub-id pub-id-type="doi">10.1126/science.aaw3616</pub-id><pub-id pub-id-type="pmid">33833097</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Gomes Dos Reis</surname><given-names>FC</given-names></name><name><surname>Bandyopadhyay</surname><given-names>G</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Ly</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>Y-J</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Ying</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CRIg<sup>+</sup> Macrophages Prevent Gut Microbial DNA-Containing Extracellular Vesicle-Induced Tissue Inflammation and Insulin Resistance</article-title><source>Gastroenterology</source><volume>160</volume><fpage>863</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.10.042</pub-id><pub-id pub-id-type="pmid">33152356</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancabelli</surname><given-names>L</given-names></name><name><surname>Milani</surname><given-names>C</given-names></name><name><surname>Lugli</surname><given-names>GA</given-names></name><name><surname>Turroni</surname><given-names>F</given-names></name><name><surname>Cocconi</surname><given-names>D</given-names></name><name><surname>van Sinderen</surname><given-names>D</given-names></name><name><surname>Ventura</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Identification of universal gut microbial biomarkers of common human intestinal diseases by meta-analysis</article-title><source>FEMS Microbiology Ecology</source><volume>93</volume><elocation-id>fix153</elocation-id><pub-id pub-id-type="doi">10.1093/femsec/fix153</pub-id><pub-id pub-id-type="pmid">29126267</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cutadapt removes adapter sequences from high-throughput sequencing reads</article-title><source>EMBnet.Journal</source><volume>17</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.14806/ej.17.1.200</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihara</surname><given-names>T</given-names></name><name><surname>Nishimura</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Nishiyama</surname><given-names>H</given-names></name><name><surname>Yoshikawa</surname><given-names>G</given-names></name><name><surname>Uehara</surname><given-names>H</given-names></name><name><surname>Hingamp</surname><given-names>P</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Ogata</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Linking Virus Genomes with Host Taxonomy</article-title><source>Viruses</source><volume>8</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.3390/v8030066</pub-id><pub-id pub-id-type="pmid">26938550</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>PS</given-names></name><name><surname>Parkin</surname><given-names>RK</given-names></name><name><surname>Kroh</surname><given-names>EM</given-names></name><name><surname>Fritz</surname><given-names>BR</given-names></name><name><surname>Wyman</surname><given-names>SK</given-names></name><name><surname>Pogosova-Agadjanyan</surname><given-names>EL</given-names></name><name><surname>Peterson</surname><given-names>A</given-names></name><name><surname>Noteboom</surname><given-names>J</given-names></name><name><surname>O’Briant</surname><given-names>KC</given-names></name><name><surname>Allen</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>DW</given-names></name><name><surname>Urban</surname><given-names>N</given-names></name><name><surname>Drescher</surname><given-names>CW</given-names></name><name><surname>Knudsen</surname><given-names>BS</given-names></name><name><surname>Stirewalt</surname><given-names>DL</given-names></name><name><surname>Gentleman</surname><given-names>R</given-names></name><name><surname>Vessella</surname><given-names>RL</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Martin</surname><given-names>DB</given-names></name><name><surname>Tewari</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Circulating microRNAs as stable blood-based markers for cancer detection</article-title><source>PNAS</source><volume>105</volume><fpage>10513</fpage><lpage>10518</lpage><pub-id pub-id-type="doi">10.1073/pnas.0804549105</pub-id><pub-id pub-id-type="pmid">18663219</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molgora</surname><given-names>M</given-names></name><name><surname>Supino</surname><given-names>D</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8</article-title><source>Immunological Reviews</source><volume>281</volume><fpage>233</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1111/imr.12609</pub-id><pub-id pub-id-type="pmid">29247989</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mrzljak</surname><given-names>A</given-names></name><name><surname>Vilibic-Cavlek</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Torque teno virus in liver diseases and after liver transplantation</article-title><source>World Journal of Transplantation</source><volume>10</volume><fpage>291</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.5500/wjt.v10.i11.291</pub-id><pub-id pub-id-type="pmid">33312890</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabet</surname><given-names>BY</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Shabason</surname><given-names>JE</given-names></name><name><surname>Wu</surname><given-names>TJ</given-names></name><name><surname>Yoon</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>BC</given-names></name><name><surname>Benci</surname><given-names>JL</given-names></name><name><surname>DeMichele</surname><given-names>AM</given-names></name><name><surname>Tchou</surname><given-names>J</given-names></name><name><surname>Marcotrigiano</surname><given-names>J</given-names></name><name><surname>Minn</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer</article-title><source>Cell</source><volume>170</volume><fpage>352</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.031</pub-id><pub-id pub-id-type="pmid">28709002</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>TTM</given-names></name><name><surname>Moufarrej</surname><given-names>MN</given-names></name><name><surname>Rasmussen</surname><given-names>M-LH</given-names></name><name><surname>Camunas-Soler</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Okamoto</surname><given-names>J</given-names></name><name><surname>Neff</surname><given-names>NF</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>RJ</given-names></name><name><surname>Downes</surname><given-names>K</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Skotte</surname><given-names>L</given-names></name><name><surname>Stevenson</surname><given-names>DK</given-names></name><name><surname>Biggio</surname><given-names>JR</given-names></name><name><surname>Elovitz</surname><given-names>MA</given-names></name><name><surname>Melbye</surname><given-names>M</given-names></name><name><surname>Quake</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Noninvasive blood tests for fetal development predict gestational age and preterm delivery</article-title><source>Science (New York, N.Y.)</source><volume>360</volume><fpage>1133</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1126/science.aar3819</pub-id><pub-id pub-id-type="pmid">29880692</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Byrd</surname><given-names>AL</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><collab>NISC Comparative Sequencing Program</collab><name><surname>Kong</surname><given-names>HH</given-names></name><name><surname>Segre</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Temporal Stability of the Human Skin Microbiome</article-title><source>Cell</source><volume>165</volume><fpage>854</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.04.008</pub-id><pub-id pub-id-type="pmid">27153496</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paisse</surname><given-names>S</given-names></name><name><surname>Valle</surname><given-names>C</given-names></name><name><surname>Servant</surname><given-names>F</given-names></name><name><surname>Courtney</surname><given-names>M</given-names></name><name><surname>Burcelin</surname><given-names>R</given-names></name><name><surname>Amar</surname><given-names>J</given-names></name><name><surname>Lelouvier</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing</article-title><source>Transfusion</source><volume>56</volume><fpage>1138</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1111/trf.13477</pub-id><pub-id pub-id-type="pmid">26865079</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Ngo</surname><given-names>TTM</given-names></name><name><surname>Camunas-Soler</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>C-X</given-names></name><name><surname>Kowarsky</surname><given-names>M</given-names></name><name><surname>Blumenfeld</surname><given-names>YJ</given-names></name><name><surname>Wong</surname><given-names>RJ</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Stevenson</surname><given-names>DK</given-names></name><name><surname>Quake</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Simultaneously Monitoring Immune Response and Microbial Infections during Pregnancy through Plasma cfRNA Sequencing</article-title><source>Clinical Chemistry</source><volume>63</volume><fpage>1695</fpage><lpage>1704</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2017.273888</pub-id><pub-id pub-id-type="pmid">28904056</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patin</surname><given-names>EC</given-names></name><name><surname>Orr</surname><given-names>SJ</given-names></name><name><surname>Schaible</surname><given-names>UE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Macrophage Inducible C-Type Lectin As a Multifunctional Player in Immunity</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>861</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.00861</pub-id><pub-id pub-id-type="pmid">28791019</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picelli</surname><given-names>S</given-names></name><name><surname>Faridani</surname><given-names>OR</given-names></name><name><surname>Björklund</surname><given-names>AK</given-names></name><name><surname>Winberg</surname><given-names>G</given-names></name><name><surname>Sagasser</surname><given-names>S</given-names></name><name><surname>Sandberg</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Full-length RNA-seq from single cells using Smart-seq2</article-title><source>Nature Protocols</source><volume>9</volume><fpage>171</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1038/nprot.2014.006</pub-id><pub-id pub-id-type="pmid">24385147</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polk</surname><given-names>DB</given-names></name><name><surname>Peek</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Helicobacter pylori: gastric cancer and beyond</article-title><source>Nature Reviews. Cancer</source><volume>10</volume><fpage>403</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/nrc2857</pub-id><pub-id pub-id-type="pmid">20495574</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poore</surname><given-names>GD</given-names></name><name><surname>Kopylova</surname><given-names>E</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Carpenter</surname><given-names>C</given-names></name><name><surname>Fraraccio</surname><given-names>S</given-names></name><name><surname>Wandro</surname><given-names>S</given-names></name><name><surname>Kosciolek</surname><given-names>T</given-names></name><name><surname>Janssen</surname><given-names>S</given-names></name><name><surname>Metcalf</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>SJ</given-names></name><name><surname>Kanbar</surname><given-names>J</given-names></name><name><surname>Miller-Montgomery</surname><given-names>S</given-names></name><name><surname>Heaton</surname><given-names>R</given-names></name><name><surname>Mckay</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>SP</given-names></name><name><surname>Swafford</surname><given-names>AD</given-names></name><name><surname>Knight</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Microbiome analyses of blood and tissues suggest cancer diagnostic approach</article-title><source>Nature</source><volume>579</volume><fpage>567</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2095-1</pub-id><pub-id pub-id-type="pmid">32214244</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potgieter</surname><given-names>M</given-names></name><name><surname>Bester</surname><given-names>J</given-names></name><name><surname>Kell</surname><given-names>DB</given-names></name><name><surname>Pretorius</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The dormant blood microbiome in chronic, inflammatory diseases</article-title><source>FEMS Microbiology Reviews</source><volume>39</volume><fpage>567</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1093/femsre/fuv013</pub-id><pub-id pub-id-type="pmid">25940667</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riquelme</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Montiel</surname><given-names>M</given-names></name><name><surname>Zoltan</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Quesada</surname><given-names>P</given-names></name><name><surname>Sahin</surname><given-names>I</given-names></name><name><surname>Chandra</surname><given-names>V</given-names></name><name><surname>San Lucas</surname><given-names>A</given-names></name><name><surname>Scheet</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Hanash</surname><given-names>SM</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Burks</surname><given-names>JK</given-names></name><name><surname>Do</surname><given-names>K-A</given-names></name><name><surname>Peterson</surname><given-names>CB</given-names></name><name><surname>Nejman</surname><given-names>D</given-names></name><name><surname>Tzeng</surname><given-names>C-WD</given-names></name><name><surname>Kim</surname><given-names>MP</given-names></name><name><surname>Sears</surname><given-names>CL</given-names></name><name><surname>Ajami</surname><given-names>N</given-names></name><name><surname>Petrosino</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>LD</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Straussman</surname><given-names>R</given-names></name><name><surname>Katz</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>JR</given-names></name><name><surname>Jenq</surname><given-names>R</given-names></name><name><surname>Wargo</surname><given-names>J</given-names></name><name><surname>McAllister</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes</article-title><source>Cell</source><volume>178</volume><fpage>795</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.07.008</pub-id><pub-id pub-id-type="pmid">31398337</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risso</surname><given-names>D</given-names></name><name><surname>Ngai</surname><given-names>J</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name><name><surname>Dudoit</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Normalization of RNA-seq data using factor analysis of control genes or samples</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>896</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1038/nbt.2931</pub-id><pub-id pub-id-type="pmid">25150836</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics (Oxford, England)</source><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salter</surname><given-names>SJ</given-names></name><name><surname>Cox</surname><given-names>MJ</given-names></name><name><surname>Turek</surname><given-names>EM</given-names></name><name><surname>Calus</surname><given-names>ST</given-names></name><name><surname>Cookson</surname><given-names>WO</given-names></name><name><surname>Moffatt</surname><given-names>MF</given-names></name><name><surname>Turner</surname><given-names>P</given-names></name><name><surname>Parkhill</surname><given-names>J</given-names></name><name><surname>Loman</surname><given-names>NJ</given-names></name><name><surname>Walker</surname><given-names>AW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reagent and laboratory contamination can critically impact sequence-based microbiome analyses</article-title><source>BMC Biology</source><volume>12</volume><elocation-id>87</elocation-id><pub-id pub-id-type="doi">10.1186/s12915-014-0087-z</pub-id><pub-id pub-id-type="pmid">25387460</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>P</given-names></name><name><surname>Malik</surname><given-names>S</given-names></name><name><surname>Laha</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Bunk</surname><given-names>S</given-names></name><name><surname>Ray</surname><given-names>JG</given-names></name><name><surname>Chatterjee</surname><given-names>R</given-names></name><name><surname>Saha</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dysbiosis of Oral Microbiota During Oral Squamous Cell Carcinoma Development</article-title><source>Frontiers in Oncology</source><volume>11</volume><elocation-id>614448</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.614448</pub-id><pub-id pub-id-type="pmid">33708627</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schierwagen</surname><given-names>R</given-names></name><name><surname>Alvarez-Silva</surname><given-names>C</given-names></name><name><surname>Servant</surname><given-names>F</given-names></name><name><surname>Trebicka</surname><given-names>J</given-names></name><name><surname>Lelouvier</surname><given-names>B</given-names></name><name><surname>Arumugam</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Trust is good, control is better: technical considerations in blood microbiome analysis</article-title><source>Gut</source><volume>69</volume><fpage>1362</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2019-319123</pub-id><pub-id pub-id-type="pmid">31203205</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>SY</given-names></name><name><surname>Singhania</surname><given-names>R</given-names></name><name><surname>Fehringer</surname><given-names>G</given-names></name><name><surname>Chakravarthy</surname><given-names>A</given-names></name><name><surname>Roehrl</surname><given-names>MHA</given-names></name><name><surname>Chadwick</surname><given-names>D</given-names></name><name><surname>Zuzarte</surname><given-names>PC</given-names></name><name><surname>Borgida</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>TT</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Kis</surname><given-names>O</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Spreafico</surname><given-names>A</given-names></name><name><surname>Medina</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Roulois</surname><given-names>D</given-names></name><name><surname>Ettayebi</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Chow</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>T</given-names></name><name><surname>Arruda</surname><given-names>A</given-names></name><name><surname>O’Kane</surname><given-names>GM</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Mansour</surname><given-names>M</given-names></name><name><surname>McPherson</surname><given-names>JD</given-names></name><name><surname>O’Brien</surname><given-names>C</given-names></name><name><surname>Leighl</surname><given-names>N</given-names></name><name><surname>Bedard</surname><given-names>PL</given-names></name><name><surname>Fleshner</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Goldenberg</surname><given-names>A</given-names></name><name><surname>Pugh</surname><given-names>TJ</given-names></name><name><surname>Hoffman</surname><given-names>MM</given-names></name><name><surname>Bratman</surname><given-names>SV</given-names></name><name><surname>Hung</surname><given-names>RJ</given-names></name><name><surname>De Carvalho</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Sensitive tumour detection and classification using plasma cell-free DNA methylomes</article-title><source>Nature</source><volume>563</volume><fpage>579</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0703-0</pub-id><pub-id pub-id-type="pmid">30429608</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>M-W</given-names></name><name><surname>Zhang</surname><given-names>N-A</given-names></name><name><surname>Shi</surname><given-names>C-P</given-names></name><name><surname>Liu</surname><given-names>C-J</given-names></name><name><surname>Luo</surname><given-names>Z-H</given-names></name><name><surname>Wang</surname><given-names>D-Y</given-names></name><name><surname>Guo</surname><given-names>A-Y</given-names></name><name><surname>Chen</surname><given-names>Z-X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SAGD: a comprehensive sex-associated gene database from transcriptomes</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D835</fpage><lpage>D840</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1040</pub-id><pub-id pub-id-type="pmid">30380119</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoji</surname><given-names>M</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Abe</surname><given-names>Y</given-names></name><name><surname>Nishise</surname><given-names>S</given-names></name><name><surname>Yaoita</surname><given-names>T</given-names></name><name><surname>Yagi</surname><given-names>M</given-names></name><name><surname>Mizumoto</surname><given-names>N</given-names></name><name><surname>Kon</surname><given-names>T</given-names></name><name><surname>Onozato</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name><name><surname>Umehara</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Koseki</surname><given-names>A</given-names></name><name><surname>Murakami</surname><given-names>R</given-names></name><name><surname>Miyano</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Ueno</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Characteristics of the gut microbiome profile in obese patients with colorectal cancer</article-title><source>JGH Open</source><volume>5</volume><fpage>498</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1002/jgh3.12529</pub-id><pub-id pub-id-type="pmid">33860101</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cancer statistics, 2015</article-title><source>CA</source><volume>65</volume><fpage>5</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.3322/caac.21254</pub-id><pub-id pub-id-type="pmid">25559415</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>TM</given-names></name><name><surname>Tharakan</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeting ADAM10 in Cancer and Autoimmunity</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>499</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.00499</pub-id><pub-id pub-id-type="pmid">32265938</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spandole</surname><given-names>S</given-names></name><name><surname>Cimponeriu</surname><given-names>D</given-names></name><name><surname>Berca</surname><given-names>LM</given-names></name><name><surname>Mihăescu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Human anelloviruses: an update of molecular, epidemiological and clinical aspects</article-title><source>Archives of Virology</source><volume>160</volume><fpage>893</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1007/s00705-015-2363-9</pub-id><pub-id pub-id-type="pmid">25680568</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Xi</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>John Lu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Noncoding RNAs Serve as Diagnosis and Prognosis Biomarkers for Hepatocellular Carcinoma</article-title><source>Clinical Chemistry</source><volume>65</volume><fpage>905</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2018.301150</pub-id><pub-id pub-id-type="pmid">30996051</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virtanen</surname><given-names>P</given-names></name><name><surname>Gommers</surname><given-names>R</given-names></name><name><surname>Oliphant</surname><given-names>TE</given-names></name><name><surname>Haberland</surname><given-names>M</given-names></name><name><surname>Reddy</surname><given-names>T</given-names></name><name><surname>Cournapeau</surname><given-names>D</given-names></name><name><surname>Burovski</surname><given-names>E</given-names></name><name><surname>Peterson</surname><given-names>P</given-names></name><name><surname>Weckesser</surname><given-names>W</given-names></name><name><surname>Bright</surname><given-names>J</given-names></name><name><surname>van der Walt</surname><given-names>SJ</given-names></name><name><surname>Brett</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name><name><surname>Millman</surname><given-names>KJ</given-names></name><name><surname>Mayorov</surname><given-names>N</given-names></name><name><surname>Nelson</surname><given-names>ARJ</given-names></name><name><surname>Jones</surname><given-names>E</given-names></name><name><surname>Kern</surname><given-names>R</given-names></name><name><surname>Larson</surname><given-names>E</given-names></name><name><surname>Carey</surname><given-names>CJ</given-names></name><name><surname>Polat</surname><given-names>İ</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Moore</surname><given-names>EW</given-names></name><name><surname>VanderPlas</surname><given-names>J</given-names></name><name><surname>Laxalde</surname><given-names>D</given-names></name><name><surname>Perktold</surname><given-names>J</given-names></name><name><surname>Cimrman</surname><given-names>R</given-names></name><name><surname>Henriksen</surname><given-names>I</given-names></name><name><surname>Quintero</surname><given-names>EA</given-names></name><name><surname>Harris</surname><given-names>CR</given-names></name><name><surname>Archibald</surname><given-names>AM</given-names></name><name><surname>Ribeiro</surname><given-names>AH</given-names></name><name><surname>Pedregosa</surname><given-names>F</given-names></name><name><surname>van Mulbregt</surname><given-names>P</given-names></name><collab>SciPy 1.0 Contributors</collab></person-group><year iso-8601-date="2020">2020</year><article-title>SciPy 1.0: fundamental algorithms for scientific computing in Python</article-title><source>Nature Methods</source><volume>17</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0686-2</pub-id><pub-id pub-id-type="pmid">32015543</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vo</surname><given-names>JN</given-names></name><name><surname>Cieslik</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Shukla</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y-M</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Engelke</surname><given-names>CG</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Robinson</surname><given-names>DR</given-names></name><name><surname>Nesvizhskii</surname><given-names>AI</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Landscape of Circular RNA in Cancer</article-title><source>Cell</source><volume>176</volume><fpage>869</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.12.021</pub-id><pub-id pub-id-type="pmid">30735636</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wetzel</surname><given-names>S</given-names></name><name><surname>Seipold</surname><given-names>L</given-names></name><name><surname>Saftig</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The metalloproteinase ADAM10: A useful therapeutic target?</article-title><source>Biochimica et Biophysica Acta. Molecular Cell Research</source><volume>1864</volume><fpage>2071</fpage><lpage>2081</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2017.06.005</pub-id><pub-id pub-id-type="pmid">28624438</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>DE</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Langmead</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Improved metagenomic analysis with Kraken 2</article-title><source>Genome Biology</source><volume>20</volume><elocation-id>257</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-019-1891-0</pub-id><pub-id pub-id-type="pmid">31779668</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Cong</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Tian</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>DD</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>QC</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation</article-title><source>Cancer Cell</source><volume>39</volume><fpage>423</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.12.012</pub-id><pub-id pub-id-type="pmid">33450198</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Shao</surname><given-names>YW</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Bao</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Alterations of circulating bacterial DNA in colorectal cancer and adenoma: A proof-of-concept study</article-title><source>Cancer Letters</source><volume>499</volume><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2020.11.030</pub-id><pub-id pub-id-type="pmid">33249197</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>DC</given-names></name><name><surname>Nottingham</surname><given-names>RM</given-names></name><name><surname>Lambowitz</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identification of protein-protected mRNA fragments and structured excised intron RNAs in human plasma by TGIRT-seq peak calling</article-title><source>eLife</source><volume>9</volume><elocation-id>e60743</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.60743</pub-id><pub-id pub-id-type="pmid">32876046</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>P</given-names></name><name><surname>Parfrey</surname><given-names>LW</given-names></name><name><surname>Yarza</surname><given-names>P</given-names></name><name><surname>Gerken</surname><given-names>J</given-names></name><name><surname>Pruesse</surname><given-names>E</given-names></name><name><surname>Quast</surname><given-names>C</given-names></name><name><surname>Schweer</surname><given-names>T</given-names></name><name><surname>Peplies</surname><given-names>J</given-names></name><name><surname>Ludwig</surname><given-names>W</given-names></name><name><surname>Glöckner</surname><given-names>FO</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The SILVA and “All-species Living Tree Project (LTP)” taxonomic frameworks</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>D643</fpage><lpage>D648</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1209</pub-id><pub-id pub-id-type="pmid">24293649</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>LG</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>QY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zong</surname><given-names>H</given-names></name><name><surname>Kang</surname><given-names>B</given-names></name><name><surname>Zou</surname><given-names>W-B</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma</article-title><source>Gut</source><volume>69</volume><fpage>540</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2019-318860</pub-id><pub-id pub-id-type="pmid">31562239</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zella</surname><given-names>D</given-names></name><name><surname>Curreli</surname><given-names>S</given-names></name><name><surname>Benedetti</surname><given-names>F</given-names></name><name><surname>Krishnan</surname><given-names>S</given-names></name><name><surname>Cocchi</surname><given-names>F</given-names></name><name><surname>Latinovic</surname><given-names>OS</given-names></name><name><surname>Denaro</surname><given-names>F</given-names></name><name><surname>Romerio</surname><given-names>F</given-names></name><name><surname>Djavani</surname><given-names>M</given-names></name><name><surname>Charurat</surname><given-names>ME</given-names></name><name><surname>Bryant</surname><given-names>JL</given-names></name><name><surname>Tettelin</surname><given-names>H</given-names></name><name><surname>Gallo</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mycoplasma promotes malignant transformation in vivo, and its DnaK, a bacterial chaperone protein, has broad oncogenic properties</article-title><source>PNAS</source><volume>115</volume><fpage>E12005</fpage><lpage>E12014</lpage><pub-id pub-id-type="doi">10.1073/pnas.1815660115</pub-id><pub-id pub-id-type="pmid">30509983</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xi</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Cai</surname><given-names>P</given-names></name><name><surname>Xing</surname><given-names>S</given-names></name><name><surname>Bao</surname><given-names>P</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Jia</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>ZJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Integrative analysis of long extracellular RNAs reveals a detection panel of noncoding RNAs for liver cancer</article-title><source>Theranostics</source><volume>11</volume><fpage>181</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.7150/thno.48206</pub-id><pub-id pub-id-type="pmid">33391469</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zozaya-Valdés</surname><given-names>E</given-names></name><name><surname>Wong</surname><given-names>SQ</given-names></name><name><surname>Raleigh</surname><given-names>J</given-names></name><name><surname>Hatzimihalis</surname><given-names>A</given-names></name><name><surname>Ftouni</surname><given-names>S</given-names></name><name><surname>Papenfuss</surname><given-names>AT</given-names></name><name><surname>Sandhu</surname><given-names>S</given-names></name><name><surname>Dawson</surname><given-names>MA</given-names></name><name><surname>Dawson</surname><given-names>S-J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Detection of cell-free microbial DNA using a contaminant-controlled analysis framework</article-title><source>Genome Biology</source><volume>22</volume><elocation-id>187</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-021-02401-3</pub-id><pub-id pub-id-type="pmid">34162397</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75181.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lo</surname><given-names>YM Dennis</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02zhqgq86</institution-id><institution>The Chinese University of Hong Kong</institution></institution-wrap><country>Hong Kong</country></aff></contrib></contrib-group></front-stub><body><p>This study provides an interesting clinical relevance of human and microbe cell free RNAs derived from plasma that can be used as biomarkers for cancer detection and cancer type classification, and thereby having potential in clinical application.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75181.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lo</surname><given-names>YM Dennis</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02zhqgq86</institution-id><institution>The Chinese University of Hong Kong</institution></institution-wrap><country>Hong Kong</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Zhong</surname><given-names>Cuncong</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/001tmjg57</institution-id><institution>University of Kansas</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Cancer Type Classification Using Plasma Cell Free RNAs Derived from Human and Microbes&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by YM Dennis Lo as the Senior Editor and Reviewing Editor. The following individual involved in review of your submission has agreed to reveal their identity: Cuncong Zhong (Reviewer #1).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. There have been many genome-wide association studies published in the field for cancer detection and cancer type classification using other technical strategies. What are the main advantages of using cfRNAs as biomarkers to distinguish cancer patients versus healthy donors, comparing with, for example, regular RNA-seq? There are already panels of genes that can be used as biomarkers for cancer patient detection and cancer type classification, based on their expression or other chemical modifications.</p><p>2. One of the main challenges in cancer detection is the ability of a technique to identify (or predict) patients at an early stage. The authors profiled samples from a cohort of ~300 patients. What percentage of the patients are at the early stage of the disease, i.e. stage I or II? What is the performance of using the featured cfRNAs as biomarkers to identify cancer patients at early stage? The author should also provide detailed clinical information of the cohort used as a supplementary.</p><p>3. In Figure 4, the authors identified cfRNAs in plasma which can be used as &quot;biomarkers&quot; to classify different cancer types, however most of them are circular RNAs. How about the expression of these &quot;biomarkers&quot; in the primary cells from the corresponding tumor types?</p><p>4. Microbial contaminations may be introduced during sample preparation. How could one be sure that the microbes detected from this study are actually from patients rather than experimental contaminations?</p><p>5. In Figure 5, the authors tried to build a predictive model of cancer detection based on cfRNAs, however, the performance of the predictive model seems very unstable, according to the AUROC, which varies from 0.4-1.0. This result greatly reduces the reliability of the machine learning model. Could they author explain why?</p><p>6. The panel of cfRNAs (both human and microbes) itself is more valuable in clinical application than the performance score of the model, if the performance is indeed as good as the authors claimed. Therefore, it will be good if the authors can present this result in more detail.</p><p>7. The language of the manuscript can be further improved. The word &quot;some&quot; is overused in many places, which is not scientific.</p><p>8. The authors need to redo the classification analysis with bootstrapping.</p><p>9. The authors need to correct their errors relating to &quot;validation&quot; and &quot;test&quot; datasets.</p><p>10. The authors need to add the patient inclusion criteria.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Chen et. al studied the use of cfRNA data for the diagnosis of five types of cancer. The authors claim that cfRNA reads from both human and microbial sources can both contribute to the cancer diagnosis. Overall, I find the hypothesis and design of the experiment reasonable. If successful, the results of this work can be used to detect major cancer types in early stages, significantly improving the survival rate of the cancer patients.</p><p>The authors need to redo the classification analysis with boosting.</p><p>The authors need to correct their errors relating to &quot;validation&quot; and &quot;test&quot; datasets.</p><p>The authors need to add the patient inclusion criteria.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>In this manuscript, Chen et al. presents clinical relevance of human and microbe cfRNAs derived from plasma, which can be used as biomarkers for cancer detection and cancer type classification. The authors profiled cfRNAs in a cohort of ~300 plasma samples of five cancer types (colorectal cancer, stomach cancer, liver cancer, lung cancer, esophageal cancer) and healthy donors with RNA-seq. They claimed a prediction rate over 0.9 for distinguishing cancer patients from healthy donors and an improvements of predictive power in cancer type classification by combining human and microbial features together. Overall, I found this study interesting and potentials in clinical application. The experiment is well designed and data properly analyzed. The presented results also support the conclusions. The motivation and potential impacts of the this study would need to be further addressed the Introduction and Discussion sections.</p><p>My main concerns are as follows:</p><p>1. There have been many genome-wide association studies published in the field for cancer detection and cancer type classification using other technical strategies. What are the main advantages of using cfRNAs as biomarkers to distinguish cancer patients versus healthy donors, comparing with, for example, regular RNA-seq? I believe there are panels of regular genes that can be used as biomarkers for cancer patient detection and cancer type classification, based on their expression or other chemical modifications.</p><p>2. One of the main challenges in cancer detection is the ability of a technique to identify (or predict) patients at an early stage. The authors profiled samples from a cohort of ~300 patients, and I am wondering what percentage of the patients are at the early stage of the disease, i.e. stage I or II? What is the performance of using the featured cfRNAs as biomarkers to identify cancer patients at early stage? The author should also provide detailed clinical information of the cohort used as a supplementary.</p><p>3. In Figure 4, the authors identified cfRNAs in plasma which can be used as &quot;biomarkers&quot; to classify different cancer types, however most of them are circular RNAs. How about the expression of these &quot;biomarkers&quot; in the primary cells from the corresponding tumor types?</p><p>4. Microbial contaminations may be introduced during sample preparation. I am not convinced whether the microbes detected from this study are actually from patients rather than experimental contaminations.</p><p>5. In Figure 5, the authors tried to build a predictive model of cancer detection based on cfRNAs, however, the performance of the predictive model seems very unstable, according to the AUROC, which varies from 0.4-1.0. This result greatly reduces the reliability of the machine learning model. Could they author explain why?</p><p>6. The panel of cfRNAs (both human and microbes) itself is more valuable in clinical application than the performance score of the model, if the performance is indeed as good as the authors claimed. Therefore, it will be good if the authors can present this result in more detail.</p><p>7. The language of the manuscript can be further improved. The word &quot;some&quot; is overused in many places, which is not scientific.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75181.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. There have been many genome-wide association studies published in the field for cancer detection and cancer type classification using other technical strategies. What are the main advantages of using cfRNAs as biomarkers to distinguish cancer patients versus healthy donors, comparing with, for example, regular RNA-seq? There are already panels of genes that can be used as biomarkers for cancer patient detection and cancer type classification, based on their expression or other chemical modifications.</p></disp-quote><p>We thank the editor and reviewer for this comment. We add the following text in Introduction:</p><p>“Most of the previous cfRNA studies focused on small RNA species<sup>20</sup>, which are relatively stable in plasma. Long RNA species in plasma have relatively low concentrations, which are mainly 100-200 nt fragments lacking poly-A tails and intact ends. Therefore, regular RNA-seq, which usually uses ligation techniques to add adaptors, will not work well for long cfRNAs. The recently developed SMART-seq<sup>21</sup> based techniques offer the potential to overcome these issues. Furthermore, to sequence total RNAs in plasma, we need to simultaneously remove the abundant rRNA fragments, which are enabled by a CRISPR-based technology called Depletion of Abundant Sequences by Hybridization (DASH)<sup>22</sup>. This motivated us to study the biological relevance and clinical utilities of human and microbe-derived long cfRNAs, taking advantage of the above techniques.”</p><p>We also add the following text in Discussion:</p><p>“Currently, various cfDNA features (e.g., fragment size, end motif, methylation) have been well applied to liquid biopsy<sup>58</sup>. Meanwhile, cfRNA provides its own advantages<sup>59</sup>. First, compared to DNAs, many RNAs are more actively transported outside of the cell through carriers such as exosomes; and some cfRNAs, such as the srpRNA RN7SL2, were reported to play regulatory rules in the cancer microenvironment<sup>60,61</sup>. As a result, cfRNA-based biomarkers may provide more functional insights. In addition, RNA expression is tissue-specific; given the dramatic changes in the RNA expression profile in tumors, a fraction of these alterations could be reflected in plasma. Furthermore, the long cfRNA sequencing used in this study detects mRNA of both DNA and RNA viruses, while neither DNA-seq nor small cfRNA-seq can. It has been reported that microbe-derived cfDNA only makes up a small fraction (lower than 0.5% in some cases) of plasma cfDNA<sup>15,16,62</sup>. The genomes of bacteria and viruses are much more compact than the human genome, and a larger fraction of their genome sequences are transcribed into RNAs. This indicates that if mixtures of human cells and microbes are sequenced by DNA-seq and RNA-seq to the same depth, microbial reads should make up a larger fraction (approximately 10% on average in our study) in the RNA-seq library, and their signals can be captured more cost-effectively. For these reasons, we believe cfRNA-seq is a cost-effective alternative to cfDNA sequencing, which provides complementary information.”</p><disp-quote content-type="editor-comment"><p>2. One of the main challenges in cancer detection is the ability of a technique to identify (or predict) patients at an early stage. The authors profiled samples from a cohort of ~300 patients. What percentage of the patients are at the early stage of the disease, i.e. stage I or II? What is the performance of using the featured cfRNAs as biomarkers to identify cancer patients at early stage? The author should also provide detailed clinical information of the cohort used as a supplementary.</p></disp-quote><p>We thank the reviewer for this suggestion. We have provided detailed clinical information of the cohort in Supplementary Table 1. In cohort design, we’ve focused on early cancer detection: for five cancer types, the majority of patients were in early stages (stage I and stage II): 83% (45 in 54) for colorectal cancer, 65% (24 in 37) for stomach cancer, 71% (44 in 62) for liver cancer, 86% (30 in 35) for lung cancer, and 71% (22 in 31) for esophageal cancer. We also evaluated the performance of our model on early-stage patients (Figure 4 A, Figure 4—figure supplement 2A-E). As expected, since the majority of patients were in the early stage, the model performance on early-stage patients was comparable with that on the whole cohort.</p><disp-quote content-type="editor-comment"><p>3. In Figure 4, the authors identified cfRNAs in plasma which can be used as &quot;biomarkers&quot; to classify different cancer types, however most of them are circular RNAs. How about the expression of these &quot;biomarkers&quot; in the primary cells from the corresponding tumor types?</p></disp-quote><p>We thank the reviewer for this comment. We have looked into the expression of these biomarkers in cells/tissues. (Please note that we have merged the previous Figure 4 to the new Figure 5 in order to better address comment 6 of the editor.)</p><p>As mentioned by the reviewer, most cancer type-specific cfRNAs identified in colorectal cancer and stomach cancer were circRNAs, we further investigate the expression of circRNAs that are specifically up-regulated in these two cancer types in tumor tissue using mioncocirc (Vo et al., 2019) data, and observed significant enrichment in both cancer types. We add the following statements in our manuscripts:</p><p>“To investigate circRNAs that are specifically upregulated in colorectal cancer and stomach cancer more systematically, we analyzed mioncocirc<sup>52</sup> data and ranked circRNAs according to fold change between tumor and normal tissue, followed by gene set enrichment analysis (GSEA) using circular RNA specifically up-regulated. In both cancer types, we found mild but significant enrichment (Figure 5—figure supplement 1E), suggesting that a subset of circRNAs upregulated in primary cancer tissue sites may enter the circulatory system and contribute to the plasma cfRNA pool.”</p><disp-quote content-type="editor-comment"><p>4. Microbial contaminations may be introduced during sample preparation. How could one be sure that the microbes detected from this study are actually from patients rather than experimental contaminations?</p></disp-quote><p>We thank the reviewer for this important comment. We did carefully prevent the bias of contamination in several ways. As shown in Figure 1 A, we combined experimental and computational methods to mitigate the impact of potential contaminations. We sequenced three samples (2 <italic>E. coli</italic> RNA samples and 1 human brain RNA sample) as negative controls for RNA extraction and library preparation, to determine identifiable lab contaminants. We also curated a list of published common lab contaminants and a list of abundant skin microbes (which could be introduced in sample collection). Microbes detected in control samples and curated potential contaminations were combined into a black list, and genera in this list were excluded from downstream analysis. We believed that these filters allow us to exclude most of the potential contaminations. For instance, some viruses with differential abundance, like HBV and TTV, are indeed biologically relevant.</p><disp-quote content-type="editor-comment"><p>5. In Figure 5, the authors tried to build a predictive model of cancer detection based on cfRNAs, however, the performance of the predictive model seems very unstable, according to the AUROC, which varies from 0.4-1.0. This result greatly reduces the reliability of the machine learning model. Could they author explain why?</p></disp-quote><p>This variability can be largely explained by the small sample size for performance evaluation in cross-validation. Therefore, following the suggestion of another reviewer (see Comments 8 of the editor), we redid the classification with bootstrapping. In each bootstrap replicate, we sampled training instances from the whole dataset with replacement, until the number of training instances reached the size of the original dataset. Now the testing set (instances that are not sampled in bootstrap) gets larger than the that in our previous version. For colorectal cancer vs. HD comparison, 50 colorectal cancer and 63 HD samples passed quality control, in theory, the size of the testing set is (1-0.632)*(50+63)≈42, much larger than the previous testing set (around 12 samples), and variability in classification performance greatly reduced (Figure 4 A, Figure 4—figure supplement 2).</p><disp-quote content-type="editor-comment"><p>6. The panel of cfRNAs (both human and microbes) itself is more valuable in clinical application than the performance score of the model, if the performance is indeed as good as the authors claimed. Therefore, it will be good if the authors can present this result in more detail.</p></disp-quote><p>We thank the reviewer for this suggestion. To better illustrate features that contribute to classification performance, we reorganized our figures. We split the original figure 5 (classification performance) into two figures, one for binary classification (now figure 4), one for multiclass classification (now figure 5), and merged the original figure 4 (cancer type-specific features) to figure 5. In general, the contribution of microbial features was more important in multiclass classification (new figure 5) than that in binary classification (new figure 4).</p><p>For pan-cancer vs. HD binary classification, we illustrated features that were recurrently identified as the top-ranked when combining human gene expression and microbe abundance in bootstrap analysis (new Figure 4C). We added the following statements in our manuscript:</p><p>“These recurrent features are dominated by human genes. Among the upregulated genes, ADAM10 (encodes a zinc-dependent protease) and TMEM165 (encodes a Golgi body transmembrane protein) have been reported to promote the invasion of tumor cells in multiple cancer types<sup>46-48</sup>. Consistent with our KEGG analysis, the downregulation of several genes that encode protein components of the ribosome (RPL8, RPS8, and RPL10A) in plasma is associated with cancer.”</p><p>As these features were dominated by human genes, when only considering microbe features, we illustrated recurrent features for pan-cancer binary classification in Figure 4—figure supplement 2F. Frequency and importance of identified features in other binary classifications (one cancer type vs. HD) were added to supplementary material.</p><p>In between cancer type classifications, we highlight the performance improvement with different color scale when adding microbial features (new Figure 5A-B). For features recurrently identified as top features in bootstrapping, we exemplified the ones with largest fold changes (new Figure 5D-E). Previously we only required the features to have large fold changes (old Figure 4), without the prediction recurrence constraint. We believe that the new figure better illustrated the features contributing to the prediction model.</p><disp-quote content-type="editor-comment"><p>7. The language of the manuscript can be further improved. The word &quot;some&quot; is overused in many places, which is not scientific.</p></disp-quote><p>We thank the reviewer for this suggestion. We’ve replaced the overused words. We’ve also hired a professional service to edit the English.</p><disp-quote content-type="editor-comment"><p>8. The authors need to redo the classification analysis with bootstrapping.</p></disp-quote><p>We thank the reviewer for this constructive suggestion. We fully agree that we cannot determine the variability in model performance with a single randomly sampled testing set, especially given the relatively small sample size. We have rerun all of the classifications with bootstrapping. In each bootstrap replicate, training instances were sampled from the original dataset with replacement, and were used for feature selection and model training. The holdout samples were used for performance evaluation. The updated results were shown in Figure 4, Figure 5, Figure 4—figure supplement 2 and Figure 5—figure supplement 1. Our previous conclusion still holds. Meanwhile, this bootstrapping procedure greatly reduces the variability of our model performance.</p><disp-quote content-type="editor-comment"><p>9. The authors need to correct their errors relating to &quot;validation&quot; and &quot;test&quot; datasets.</p></disp-quote><p>We thank the reviewer for pointing out this, we have changed our notation for different datasets. Now we clarified the nomenclature in the revised manuscript and replaced “validation set” with “test set”.</p><disp-quote content-type="editor-comment"><p>10. The authors need to add the patient inclusion criteria.</p></disp-quote><p>We thank the reviewer for this suggestion. We’ve added the following patient inclusion criteria in method section:</p><p>“The criteria for inclusion were pathologically diagnosed colorectal cancer, stomach cancer, liver cancer, lung cancer and esophageal cancer patients before surgery, radiation and chemotherapy.”</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Chen et. al studied the use of cfRNA data for the diagnosis of five types of cancer. The authors claim that cfRNA reads from both human and microbial sources can both contribute to the cancer diagnosis. Overall, I find the hypothesis and design of the experiment reasonable. If successful, the results of this work can be used to detect major cancer types in early stages, significantly improving the survival rate of the cancer patients.</p></disp-quote><p>We thank the reviewer for the overall positive comments and constructive suggestions. The editor has summarized the major points as comments 8-10 in “essential revisions”, please refer to comments 8-10 in “Response to editor” section for point-to-point responses.</p><disp-quote content-type="editor-comment"><p>The authors need to redo the classification analysis with boosting.</p></disp-quote><p>Please see response to comment 8 of the editor.</p><disp-quote content-type="editor-comment"><p>The authors need to correct their errors relating to &quot;validation&quot; and &quot;test&quot; datasets.</p></disp-quote><p>Please see response to comment 9 of the editor.</p><disp-quote content-type="editor-comment"><p>The authors need to add the patient inclusion criteria.</p></disp-quote><p>Please see response to comment 10 of the editor.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>In this manuscript, Chen et al. presents clinical relevance of human and microbe cfRNAs derived from plasma, which can be used as biomarkers for cancer detection and cancer type classification. The authors profiled cfRNAs in a cohort of ~300 plasma samples of five cancer types (colorectal cancer, stomach cancer, liver cancer, lung cancer, esophageal cancer) and healthy donors with RNA-seq. They claimed a prediction rate over 0.9 for distinguishing cancer patients from healthy donors and an improvements of predictive power in cancer type classification by combining human and microbial features together. Overall, I found this study interesting and potentials in clinical application. The experiment is well designed and data properly analyzed. The presented results also support the conclusions. The motivation and potential impacts of the this study would need to be further addressed the Introduction and Discussion sections.</p></disp-quote><p>We thank the reviewer for the positive feedback and constructive suggestions. We’ve added more discussion on motivation and potential impacts of this study in the introduction and Discussion section.</p><p>In introduction section:</p><p>“As total RNA-seq captures RNA fragments regardless of their origination, profiling total cfRNAs should provide rich information for both human and microbe transcripts. …”.</p><p>In Discussion section:</p><p>“We demonstrated that there are biologically relevant differences between cfRNA of healthy donors and cancer patients…Our work highlights the feasibility of discovering clinically relevant but understudied viruses from high throughput sequencing data…we believe cfRNA-seq is a cost-effective alternative to cfDNA sequencing, which provides complementary information.”</p><p>The remaining 7 major points were summarized as comments 1-7 by the editor in the essential revisions list, please refer to comments 1-7 in “Response to editor” section for point-to-point responses.</p><disp-quote content-type="editor-comment"><p>My main concerns are as follows:</p><p>1. There have been many genome-wide association studies published in the field for cancer detection and cancer type classification using other technical strategies. What are the main advantages of using cfRNAs as biomarkers to distinguish cancer patients versus healthy donors, comparing with, for example, regular RNA-seq? I believe there are panels of regular genes that can be used as biomarkers for cancer patient detection and cancer type classification, based on their expression or other chemical modifications.</p></disp-quote><p>Please see response to comment 1 of the editor.</p><disp-quote content-type="editor-comment"><p>2. One of the main challenges in cancer detection is the ability of a technique to identify (or predict) patients at an early stage. The authors profiled samples from a cohort of ~300 patients, and I am wondering what percentage of the patients are at the early stage of the disease, i.e. stage I or II? What is the performance of using the featured cfRNAs as biomarkers to identify cancer patients at early stage? The author should also provide detailed clinical information of the cohort used as a supplementary.</p></disp-quote><p>Please see response to comment 2 of the editor.</p><disp-quote content-type="editor-comment"><p>3. In Figure 4, the authors identified cfRNAs in plasma which can be used as &quot;biomarkers&quot; to classify different cancer types, however most of them are circular RNAs. How about the expression of these &quot;biomarkers&quot; in the primary cells from the corresponding tumor types?</p></disp-quote><p>Please see response to comment 3 of the editor.</p><disp-quote content-type="editor-comment"><p>4. Microbial contaminations may be introduced during sample preparation. I am not convinced whether the microbes detected from this study are actually from patients rather than experimental contaminations.</p></disp-quote><p>Please see response to comment 4 of the editor.</p><disp-quote content-type="editor-comment"><p>5. In Figure 5, the authors tried to build a predictive model of cancer detection based on cfRNAs, however, the performance of the predictive model seems very unstable, according to the AUROC, which varies from 0.4-1.0. This result greatly reduces the reliability of the machine learning model. Could they author explain why?</p></disp-quote><p>Please see response to comment 5 of the editor.</p><disp-quote content-type="editor-comment"><p>6. The panel of cfRNAs (both human and microbes) itself is more valuable in clinical application than the performance score of the model, if the performance is indeed as good as the authors claimed. Therefore, it will be good if the authors can present this result in more detail.</p></disp-quote><p>Please see response to comment 6 of the editor.</p><disp-quote content-type="editor-comment"><p>7. The language of the manuscript can be further improved. The word &quot;some&quot; is overused in many places, which is not scientific.</p></disp-quote><p>Please see response to comment 7 of the editor.</p></body></sub-article></article>